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Abbreviations 
ABCB1: ATB-binding cassette sub-family B member 1; CC: column chromatography; CMV: 
cytomegalovirus; FAR: fluorescence activity ratio; FIX: fractional inhibitory index; HJB: 17-
hydroxyjolkinolide; JAK: Janus kinase; LPS: lipopolysaccharide; MAPK: mitogen-activated 
protein kinase; MDR: multidrug resistance; MPP+: 1-methyl-4-phenylpyridinium-ion; NF-κB: 
nuclear factor; PKC: protein kinase C; P-gp: P-glycoprotein; PTX: paclitaxel; STAT: signal 
transducer and activator of transcription; TLC: thin layer chromatography, TNF-α: tumor 
necrosis factor; TRPV1: transient receptor potential vanilloid 1; VEGF: vascular endothelial 
growth factor 
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1. Introduction 
The Euphorbiaceae is one of the largest families of higher plants, comprising about 50 
tribes, 300 genera and 7500 species, with probably the highest species richness in many 
habitats.1 The genus Euphorbia is one of the 6 largest genera (Astragalus, Bulbophyllum, 
Psychotria, Euphorbia, Carex, Begonia) of flowering plants, with approximately 2160 species, 
subdivided into many subgenera and sections. Members of this genus are characterized by 
the production of a milky irritant latex.2 The Euphorbia species are widely distributed 
throughout mainlands (both tropical and temperate regions) and range in morphology from 
small, annual or perennial herbaceous plant to woody shrubs, lianas, and trees and even 
large desert succulents.3 In general, the whole plants, stems, leaves, latex, roots, and seeds 
of Euphorbia species were investigated in chemical and pharmacological studies.1,2 The 
genus consists species of great economic importance, such as Euphorbia tetragonal and E. 
triangularis (inferior rubber), E. antisyphylitica (candellila wax)and Euphorbia resinifera 
(‘euphorbium’).4 
Diterpenes occurring in plants of the genus Euphorbia are in the focus of natural 
product drug discovery because of the wide range of their therapeutically relevant biological 
activities (e.g. antitumor, cytotoxic, multidrug resistance-reversing, antiviral properties, 
various vascular effects and anti-inflammatory activity)5 and their great structural diversity, 
resulting from various macrocyclic and polycyclic skeletons (e.g. jatrophane, ingenane, 
daphnane, tigliane, lathyrane, etc.) and oxygen-containing functionalities, including different 
aliphatic (e.g. acetyl, n-butanoyl, isobutanoyl, methylbutanoyl, tiglyl, angeloyl, isovaleroyl, 
etc.) and aromatic (benzoyl and nicotinoyl) acids. Diterpenes are considered to be important 
taxonomic markers, because of their limited occurrence; these types of diterpenes are 
specific to the Thymelaeaceae and Euphorbiaceae families. Over 650 diterpenoids, 
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incorporating more than 20 skeletal types, have been isolated from Euphorbia plants. In 
2008, Shi et al. summarized the diterpenes isolated previously from different Euphorbia 
species.6 The present review covers 221 new Euphorbia diterpenes isolated since then; the 
structures of the new diterpenoids are presented. 
Among Euphorbia diterpenes ingenol 3-angelate (ingenol mebutate, PEP005, Picato®, 
LEO Pharma) attracted the greatest interest in the last years, because it was approved by the 
FDA in 2012, and the EMA in 2013 for the treatment of actinic keratosis, a precancerous skin 
condition.7 Besides this compound, other promising diterpenes (e.g. some phorbol and 
ingenol derivatives) are under clinical investigations. In particular, prostratin is of 
considerable interest because of its unique ability to activate latent viral reservoirs, and 
preventing healthy cells from infection. These types of compounds reactivate HIV-1 latency 
by protein kinase C (PKC)-dependent NF-κB activation, and help to avoid the new infection of 
CD4+ cells.8 Resiniferatoxin, an ultrapotent capsaicin analogue belonging in the daphnane 
group, is currently under phase II and III clinical evaluation.9 
In Chinese pharmacopoeias five species, E. pekinensis, E. kansui, E. lathyris, E. 
humifusa and E. maculata are official. These species are well-known poisonous plants, but in 
the traditional Chinese medicine they are recommended for the treatment of edema, 
gonorrhea, migraine and warts.10 
 
2. Isolation and analytics of diterpenes 
 
Diterpenes are generally isolated from different Euphorbia species by very similar 
protocols (Table 1). All parts of the plants may accumulate diterpenoids. The roots, leaves, 
stems, fruits, seeds and whole plants are equally studied. In general: extraction of the plant 
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materials is carried out at room temperature by maceration, and the extracts are evaporated 
at reduced pressure below 45 °C. As the plants commonly produce complex mixtures of 
esters of one or more similar diterpene nuclei, their isolation requires a multistep separation 
protocol. 
The plant material is usually initially extracted with 95% EtOH or MeOH. Then, after 
removal of the solvent, the residue is dissolved in water for partition between solvents with 
different polarities (e.g. petroleum ether and CHCl3 or CH2Cl2). When plant extracts are 
prepared from herbaceous starting material, purification of the chloroform fractions [e.g. 
with solid-phase extraction (SPE) on polyamide] is necessary to remove chlorophyll. In the 
next step, column chromatography is used, usually on silica gel with gradient elution. 
Repeated column chromatography (CC) separations, utilizing different adsorbents (normal- 
and reversed-phase silica gel and Sephadex LH-20 gel), have been applied successfully for 
the purification of components of complex mixtures. For final purification, preparative TLC 
and normal- and/or reversed-phase HPLC are used. 
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Table 1. Isolation methods of Euphorbia diterpenes 
Type of 
diterpene 
Plant Plant 
part 
Extraction 
solvent 
Partitioning 
solvent 
CC mobile 
phase 
TLC developing systems HPLC Ref 
Rosane E. ebracteolata root 
(dried) 
95% EtOH petroleum 
ether, CHCl3 
petroleum 
ether–Me2CO 
(100:0 to 0:100) 
n.d. RP-HPLC 
MeOH–H2O (95:5) 
81 
ent-Abietane E. fischeriana root 
(dried) 
95% EtOH petroleum 
ether, 
CHCl3, n-
BuOH 
petroleum 
ether–Me2CO 
n.d. – 68 
 E. formosana aerial 
parts 
(dried) 
MeOH CHCl3 n-hexane–
EtOAc–MeOH 
n.d. NP-HPLC  
n-hexane–EtOAc– 
Me2CO–CH2Cl2 
(25:6:4:10),  
n-hexane–Me2CO 
(5:1 and 7:3) 
23 
 E. guyoniana root 
(dried) 
CHCl3 n.d. petroleum 
ether–EtOAc 
pertroleum ether–EtOAc 
(85:15) 
– 22 
 E. neriifolia stem 
(dried) 
90% EtOH petroleum 
ether, 
EtOAc, n-
BuOH 
petroleum 
ether–Me2CO 
(9:1 to 1:9) 
n.d. – 27 
 E. retusa root 
(dried) 
CH2Cl2  n-hexane–
EtOAc (100:0 to 
0:100) 
n.d. MeCN–H2O (4:1) 21 
ent-Kaurane E. fischeriana root 
(dried) 
95% EtOH EtOAc petroleum 
ether–Me2CO 
n.d. – 24 
  root 
(dried) 
95% EtOH petroleum 
ether, 
petroleum 
ether–EtOAc 
n.d. – 25 
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CHCl3, 
EtOAc 
(100:1 to 1:2) 
 E. hirta whole 
plant 
(dried) 
95% EtOH EtOAc petroleum 
ether–Me2CO 
(1:0 to 0:1) 
n.d. – 26 
 E. neriifolia stem 
(dried) 
90% EtOH petroleum 
ether, 
EtOAc, n-
BuOH 
petroleum 
ether–Me2CO 
(9:1 to 1:9) 
n.d. – 27 
Dimer E. yinshanica root 
(fresh) 
85% EtOH EtOAc CHCl3–Me2CO 
(40:1 to 1:1) 
n.d. – 29 
Casbane E. pekinensis root 
(dried) 
95% EtOH  CHCl3 petroleum 
ether–EtOAc 
petroleum ether–EtOAc 
(98:2) 
– 10 
Jatrophane E. bungei aerial 
parts 
(dried) 
Me2CO CH2Cl2 petroleum 
ether–EtOAc 
n.d. NP-HPLC 
petroleum ether–
EtOAc (1:1) 
44 
 E. dendroides aerial 
parts 
(dried) 
60% EtOH n-hexane toluene–EtOAc  n-hexane–Me2CO (7:3) – 46 
 E. esula whole 
plant 
(fresh) 
MeOH CH2Cl2 cyclohexane–
EtOAc–EtOH 
cyclohexane–EtOAc–
EtOH (5:5:2) 
RP-HPLC MeCN–
H2O (3:2) 
43 
 E. guyoniana aerial 
parts 
(dried) 
CH2Cl2–
MeOH 
(1:1) 
n.d. n-hexane–
CH2Cl2, CH2Cl2– 
MeOH 
n.d. – 32 
 E. guyoniana aerial 
parts 
(dried) 
CH2Cl2-
MeOH 
(1:1) 
n.d. n-hexane–
CH2Cl2 (25:75) 
n.d. RP-HPLC 
MeOH–H2O (7:3) 
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 E. helioscopia whole 
plant 
EtOH petroleum 
ether, 
petroleum 
ether–EtOAc 
n.d. – 35 
9 
(dried) EtOAc 
 E. helioscopia whole 
plant 
(dried) 
95% EtOH petroleum 
ether 
petroleum 
ether–CHCl3, 
CHCl3–MeOH 
n.d. RP-HPLC 
MeOH–H2O (65:35) 
34 
 E. kansui root 
(n.d.) 
95% EtOH EtOAc petroleum 
ether–EtOAc 
n.d. – 12 
 E. peplus whole 
plant 
(dried) 
95% EtOH petroleum 
ether 
petroleum 
ether–Me2CO 
(100:0 to 0:100) 
n.d. – 45 
 E. sororia fruit 
(dried) 
MeOH petroleum 
ether 
n.d. n.d. – 41 
 E. sororia whole 
plant 
(dried) 
MeOH petroleum 
ether 
n.d. n.d. – 42 
 E. tuckeyana whole 
plant 
(dried) 
MeOH EtOAc n-hexane–
EtOAc (1:0, 
19:1, 4:1, 7:3, 
2:3, 1:1, 2:3, 
1:9, 0:1) 
CHCl3–MeOH (19:1), 
CH2Cl2–Me2CO (19:1) 
RP-HPLC 
MeOH–H2O (13:7, 
7:3, 3:2, 11:9) 
33 
Lathyrane E. aellenii aerial 
parts 
(dried) 
MeOH CHCl3, 
EtOAc, n-
BuOH 
n-hexane–
CHCl3, n-
hexane–EtOAc 
CHCl3–Me2CO (97:3) – 54 
 E. bungei aerial 
parts 
(dried) 
Me2CO CH2Cl2 petroleum 
ether–EtOAc 
n.d. NP-HPLC 
petroleum ether–
EtOAc (1:1) 
44 
 E. helioscopia whole 
plant 
(n.d.) 
30% 
MeOH 
 n.d. n.d. – 53 
 E. kansuensis root 
(dried) 
85% 
EtOH, 
CHCl3 petroleum 
ether, 
n.d. – 48 
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85ºC petroleum 
ether–EtOAc 
(24:1 to 9:16), 
EtOAc 
 E. lactea latex 
(fresh) 
EtOAc – n-hexane–
EtOAc 
n-hexane–Me2CO (9:1) – 56 
 E. lagascae whole 
plant 
(dried) 
MeOH Et2O n-hexane–
EtOAc (1: to 
0:1) EtOAc–
MeOH (19:1 to 
1:4) 
CHCl3–MeOH (19:1) RP-HPLC 
MeOH–H2O (4:1, 
7:3 and 13:7) 
47 
 E. lathyris seed 
(fresh) 
95% EtOH EtOAc RP MeOH–H2O 
(7:3) 
n.d. – 49 
 E. lathyris seed 
(fresh) 
95% EtOH EtOAc petroleum 
ether–EtOAc 
n.d. – 50 
 E. lathyris seed 
(fresh) 
95% EtOH EtOAc, n-
BuOH 
petroleum 
ether–EtOAc 
n.d. – 51 
 E. laurifolia latex 
(fresh) 
EtOAc – n-hexane–
EtOAc 
n-hexane–Me2CO (85:15) – 56 
 E. micractina root 
(dried) 
95% EtOH n.d. n.d. n.d. RP-HPLC 
MeOH-H2O (4:1) 
55 
 E. neriifolia leaves 
(dried) 
MeOH n-hexane, 
EtOAc, 
BuOH 
n.d. n.d. RP-HPLC MeCN–
H2O (6:4) 
58 
 E. prolifera root 
(dried) 
MeOH EtOAc petroleum 
ether–Me2CO 
(99:1 to 6:4) 
n.d. RP-HPLC MeOH-
H2O (84:16) 
57 
 E. royleana aerial 
parts 
(dried) 
70% 
MeCN 
EtOAc petroleum 
ether–Me2CO 
(1:0 to 1:1) 
n.d. RP-HPLC MeOH-
H2O (85:15, 8:2, 
76:24 and 73:27) 
52 
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Myrsinane E. aellenii aerial 
parts 
(dried) 
MeOH CHCl3, 
EtOAc, n-
BuOH 
n-hexane–CHCl3 
(0 to 100) 
n.d. NP-HPLC n-
hexane–EtOAc 
(7:3) 
60 
 E. falcata whole 
plant 
(fresh) 
MeOH CHCl3 cyclohexane–
EtOAc–MeOH 
(8:2:0 to 0:0:1) 
n-hexane–Me2CO (7:3), 
CHCl3–Me2CO (49:1) 
– 66 
 E. macroclada aerial 
parts 
(dried) 
EtOAc petroleum 
ether, 
CH2Cl2 
heptane–CHCl3 n.d. NP-HPLC 
pertroleum ether–
EtOAc (7:3 and 6:4) 
74 
 E. prolifera root 
(dried) 
95% EtOH petroleum 
ether, 
EtOAc 
petroleum 
ether–Me2CO 
(9:1 to 1:1) 
n.d. – 61 
 E. prolifera root 
(dried) 
MeOH EtOAc petroleum 
ether–Me2CN 
(99:1 to 3:2) 
n.d. RP-HPLC MeOH–
H2O (3:2, 3:1, 4:1) 
62, 
63, 
64 
Tigliane E. aellenii aerial 
parts 
(dried) 
MeOH CHCl3, 
EtOAc, n-
BuOH 
n-hexane–CHCl3 
(1:0 to 0:1) 
n.d. – 71 
 E. cornigera root 
(dried) 
Me2CO EtOAc, 
petroleum 
ether–
MeOH–H2O 
15:10:0.5 
n-hexane–
EtOAc (19:1, 
9:1, 4:1, 7:3, 
1:1, 1:3) 
n-hexane–Et2O–EtOAc 
(4:3:3) 
RP-HPLC H2O–
MeCN (gradient 
88%→96%) 
72 
 E. fischeriana root 
(dried) 
95% EtOH CHCl3 petroleum 
ether–Me2CO 
(50:1 to 1:1) 
n.d. – 69 
 E. grandicornis aerial 
parts 
(fresh) 
MeOH CHCl3 n-hexane– 
Me2CO (9:1 to 
3:7) 
n-hexane–Me2CO (13:7) RP-HPLC MeOH–
H2O (4:1) 
70 
 E. macroclada aerial EtOAc petroleum heptane–CHCl3 n.d. NP-HPLC 74 
12 
parts 
(dried) 
ether, 
CH2Cl2 
petroleum ether–
EtOAc (7:3 and 6:4) 
Ingenane E. cauducifolia latex 
(fresh) 
95% 
MeOH 
Et2O, EtOAc n-hexane–
EtOAc (19:1 to 
0:1) 
n-hexane–Et2O–EtOAc 
(4:3:3) 
RP-HPLC MeCN–
H2O gradient 
80 
 E. cornigera root 
(dried) 
MeOH EtOAc EtOAc–CHCl3, 
EtOAc–MeOH 
n-hexane–Et2O–EtOAc 
4:3:3 
RP-HPLC H2O–
MeCN and MeOH–
H2O gradient 
78 
 E. cornigera shoot 
(dried) 
MeOH n-hexane, 
CHCl3, Et2O, 
EtOAc, n-
BuOH 
CH2Cl2–EtOAc,–
MeOH (9:1:0 to 
0:1:9) 
CH2Cl2–EtOAc,–MeOH 
(6:3:1) 
RP-HPLC MeCN–
H2O gradient 
79 
 E. esula whole 
plant 
(dried) 
95% EtOH petroleum 
ether, 
EtOAc 
n.d. CHCl3–EtOAc (10:1) – 75 
 E. kansui whole 
plant 
(dried) 
95% and 
50% EtOH 
petroleum 
ether– 
Me2CO (e.g. 
50:1) 
n.d. n.d. – 11 
 E. kansui root 
(dried) 
EtOH n-hexane, 
EtOAc 
n-hexane–
EtOAc 
CHCl3–MeOH (96:4) – 77 
 E. kansui root 
(dried) 
95% EtOH EtOAc petroleum 
ether–EtOAc 
n.d. – 12 
 E. laurifolia latex 
(fresh) 
EtOAc n.d. n-hexane–
EtOAc 
n-hexane–acetone 
(85:15) 
– 56 
 E. splendida aerial 
parts 
(fresh) 
MeOH n-hexane, 
CHCl3, n-
BuOH 
n-hexane–
EtOAc 
CHCl3–Me2CO – 59 
Paraliane and 
pepluane 
E. paralias n.d. EtOAc n.d. n.d. n.d. – 82 
n.d. not described
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In the case of E. kansui, a unique extraction method has been described in the 
literature.11 The toxicity of this plant has long been known; even so, it has been used in the 
traditional Chinese medicine for the treatment of edema, ascites and cancer. The toxicity 
proved to be greatly reduced by cooking the plant with rice vinegar. In the course of the 
investigation of the constituents of this plant, the dried herb was soaked with rice vinegar. 
When the rice vinegar had been completely absorbed, the material was heated in a pot over 
a fire, then dried and crushed. Conventional separation techniques were subsequently used. 
Unfortunately, in this way only one ingenane derivative was isolated from 13 kg of plant 
material.11 
Zhang et al. elaborated a simple and rapid LC-DAD-ESI-MS-MS method for the 
separation and identification of the main diterpenes of E. kansui roots. In the 
proinflammatory fraction of the plant twelve compounds were successfully separated on a 
C18 reversed-phase column with a gradient mobile phase, and identified on the basis of 
spectral data.12 
Tang et al. established a method for the simultaneous determination of ten 
diterpenes (prostratin, neriifolene, antiquorin, kaurane-3,16,17-triol, ent-atisane-3β,16α,17-
triol, ent-16α,17-dihydroxyatisan-3-one, kauranoic acid, jolkinolide A and B and ent-16β-H-3-
oxo-kauran-17-ol) of E. fischeriana by RP-HPLC using evaporative light scattering detection.13 
Four samples of the plant prepared by different extraction methods were investigated. The 
relationship between the proinflammatory toxicity and the content of diterpenes in different 
samples was also discussed. In contrast to the dried roots, the fresh roots contained a much 
greater quantity of prostratin, which demonstrated a higher proinflammatory effect than 
other diterpenes. But the authors did not discuss in detail the reason behind this 
phenomenon. It was also concluded that the dried roots are suitable for ordinary therapy so 
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as to avoid the intense stimulation of cell proliferation and NO production, while the fresh 
roots, containing more effective compounds (e.g. jolkinolide A and B) could be used in the 
antitumor therapy.13 
 
3. Isolated diterpenoids 
 
3.1. Higher diterpenoids 
 
Among the diterpene constituents of the family Euphorbiaceae, the nonspecific 
‘higher diterpenes’ may be mentioned. The skeletons of these compounds involve the 
classical ‘concertina-like’ cyclization of the precursor to form the variously cyclized 
hydrocarbon structures of many diterpenoids, triterpenoids and steroids.14 Higher 
diterpenes, such as the bicyclic labdane and clerodane, the tricyclic abietane, and the 
tetracyclic atisane, kaurane, and bayerane types are not specific compounds of 
Euphorbiaceae species, these occur in many other plant families, too (Figure 1).15 
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Figure 1. Skeletal types of Euphorbia diterpenes 
 
3.1.1. Rosanes, ent-abietanes, atisanes and ent-kauranes 
 
The tricyclic rosanes, which arise from migration of the C-10 methyl group of 
pimaranes to C-9, occur predominantly in higher plants.16 Abietane diterpenoids of the 
Euphorbiaceae family are usually substituted with an α,β-unsaturated γ-lactone ring 
connected in position C-12 and C-13. Some carbons of these diterpenes, especially C-8, C-14, 
C-11 and C-12, usually form double bonds or are substituted with hydroxy or keto groups.17 
Kauranes and atisanes are important groups of tetracyclic diterpenes; their structures 
rosane abietane atisane 
kaurane casbane 
jatrophane lathyrane 
myrsinane premyrsinane 
cyclomyrsinane 
daphnane ligliane ingenane 
pepluane 
16 
comprise a perhydrophenanthrene unit (A, B and C rings) fused with a cyclopentane (in 
kauranes) or cyclohexane (in atisanes) unit (D ring) formed by a bridge of two carbons 
between C-8 and C-13 (in kauranes) or between C-8 and C-12 (in atisanes) (Table 2).18 
The new rosane-type diterpenoid (1) isolated from E. ebracteolata by Deng et al.19 
differs from 18-hydroxyhugorosenone, isolated previously from Hugonia casteneifolia 
(Linaceae), only in its stereochemistry.20 
Six ent-abietane-type diterpenes (retusolide A–F, 5–10) were reported from E. retusa, 
among them retusolide F (10) was identified as the first example of a rearranged ent-
abietane lactone of plant origin.21 Haba et al. isolated two new ent-abietane diterpenoids 
(11 and 12) from the roots of E. guyoniana.22 From the chloroform fraction of the aerial parts 
of E. formosana, two new (3, and the seco-helioscopinolide 4) and four known 
[helioscopinolide A–C and ent-(5β,8α,9β,10α,12α)-12-hydroxyatis-16-ene-3,14-dione] 
diterpenoids were isolated by YU et al.23 
Qi-Cheng et al. obtained eight known diterpenoids (jolkinolide A and B, prostratin, 
ent-kaurane-3-oxo-16α,17-diol, antiquorin, neriifolene, ent-atisane-3β,16α,17-triol and 
kauranoic acid) from the roots of E. fischeriana,24 and four known diterpenoids (jolkinolide B, 
12-deoxyphorbol 13-(9Z)-octadecanoate 20-acetate and 17-hydroxyjolkinolide A and B) were 
later isolated from this plant by Geng et al.25 
A phytochemical study of the ethanol extract of E. hirta led to the isolation of one 
new (18) and two known (2β,16α-dihydroxy-ent-kaurane and 16α,19-dihydroxy-ent-kaurane) 
ent-kaurane diterpenoids.26 Liu et al. isolated nine diterpenoids (eight of them were new 
compounds) including two ent-3,4-seco-kaurane-type diterpenoids (19 and 20), three 
atisane derivatives (13–15), two 3,4-seco-atisane-type diterpenoids (16 and 17) and one ent-
17 
abietane-type (2) diterpene from the stems of E. neriifolia. The absolute configurations of 19 
and 20 were determined by X-ray crystallography.27 
Wu et al. investigated the constituents of E. fischeriana and isolated ent-kaurane-3-
oxo-16α,17-diol, antiquorin, neriifolene, ent-atisane-3β,16α,17-triol and kaurenoic acid for 
the first time from the roots of the plant.28 
 
3.1.2. Dimeric higher diterpenes 
 
In 2012, Zhang et al. investigated the secondary metabolites of E. yinshanica, a plant 
used in traditional Tibetan medicine for the treatment of exanthema, furuncles and 
cutaneous anthrax, and as a purgative agent. From the EtOAc extract of the fresh roots of 
the plant, two novel diterpene dimers [bisyinshanic acids A (21) and B (22)] with a 
bismagdalenic acid skeleton were isolated.29 
 
3.2. Lower diterpenoids 
 
The macrocyclic diterpenes and their cyclization products can be classified as ‘lower 
terpenes’ (‘Euphorbiaceae diterpenes’), derived from a geranylgeranyl pyrophosphate 
precursor through a ‘head-to-tail’ cyclization.30 The functionalization of diterpenes 
presumably proceeds after cyclization. The cembrene cation is a very reactive intermediate 
containing a 14-membered ring, which is stabilized through the formation of cembranoids.31 
Lower diterpenoids are characteristic compounds of Euphorbiaceae and Thymelaeaceae and 
are of chemotaxonomic relevance. 
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3.2.1. Casbanes 
 
Casbanes are macrocyclic diterpenes containing a 14-membered and a cyclopropane 
ring. They have been considered to be precursors of a number of macrocyclic diterpenes. 
Liang et al. isolated a new casbane diterpenoid (pekinenal, 23) from E. pekinensis. Its 
absolute configuration was determined by X-ray crystallography.10 
 
3.2.2. Jatrophanes 
 
Jatrophane diterpenes occur exclusively in the Euphorbiaceae family, in general in 
form of polyesters. These macrocyclic compounds are based on a 
bicyclo[10.3.0]pentadecane skeleton, without the presence of a cyclopropane ring. Their 
great structural variability stems from the number and positions of the double bonds, the 
nature and number of the oxygen functions, and the configuration of the diterpene core. 
The oxygen functions can be hydroxy, keto, epoxy, ether and ester groups. Natural 
jatrophane diterpenes are mainly polyacylated derivatives, the number of ester moieties 
ranging between three [guyonianin E (46)] and eight [esulatin H (54)]. The acyl residues are 
most frequently acetyl, benzoyl, isobutanoyl, 2-methylbutanoyl or nicotinoyl, and rarely 
propionyl, butanoyl, angeloyl, tigloyl or cinnamoyl. The most heterogeneously esterified 
molecules are euphopeplin A (26), 32 and 34, containing four different acyl groups. 
Depending on their substitution, jatrophanes may have 5–10 chiral centers. Jatrophane 
diterpenes do not form a stereochemically homogeneous series, because the configurations 
of the carbons are variable. 
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El-Bassuony isolated two new jatrophane-type diterpenes, guyonianin C (29) and D 
(31), from the aerial parts of E. guyoniana.5 Later, Hegazy et al. also investigated the 
chemical constituents of this species and isolated two new [guyonianins E (46) and F (47)] 
and one known jatrophane diterpenes from the aerial parts of the plant. E. guyoniana is 
used traditionally in Algeria for curing the venomous bites of scorpions and for removing 
warts.32 
From the methanol extract of E. tuckeyana, Duarte et al. isolated three new 
jatrophane-type diterpenes: tuckeyanol A (44) and B (45), and euphotuckeyanol (30).33 In 
the same year, Tao et al. isolated one new (euphornin L, 24) and seven known jatrophane-
type macrocyclic diterpenes from E. helioscopia. This plant has been used to treat malaria, 
bacillary dysentery, osteomyelitis and tumors in Chinese folk medicine.34 Later, Geng et al. 
also isolated jatrophane diterpenes [euphornin L (24) and N (25)] from this plant.35 Such 
diterpenes (with a 5E,11E-diene structure) have previously been isolated only from four 
Euphorbia species (E. serrulata, E. platyphyllos, E. helioscopia and E. pubescens).36–39 
A new macrocyclic diterpenoid, kansuinine J (53), was isolated from the roots of E. 
kansui by Guo et al. This is the first jatrophane type diterpene reported in the literature, 
esterified with an isopentenoyl group.40 
From the fruits of E. sororia, six new jatrophane diterpenes esterified with six or 
seven acyl groups (27, 28, 37–40) were isolated by Huang et al. The seeds of this plant have 
been used in traditional Chinese medicine for the treatment of abdominal pain and 
distention, skin disease and paralysis. It has also been administered to improve intelligence 
and appetite.41 Phytochemical investigations of the whole plant resulted in three new 
bishomojatrophane diterpenoids, sororianolides A–C (55–57).42 
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Phytochemical studies of the whole, undried plant of E. esula led to the isolation of 
six new jatrophane diterpene polyesters, esulatins H–M (41–43, 48, 49 and 54), together 
with three known compounds.43 Shokoohinia et al. isolated two new (50 and 51) and one 
known jatrophane diterpenoids from the acetone extract of the aerial parts of E. bungei.44 
Phytochemical investigation of E. peplus led to the isolation of a new jatrophane 
diterpenoid, euphopeplin A (26), in addition to two known jatrophanes.45 Aljancic et al. 
isolated six new compounds (euphodendrophanes A–F, 32–36 and 52) from E. dendroides, a 
small tree located in the Mediterranean region.46 
 
3.2.3. Lathyranes 
 
One of the largest groups of tricyclic diterpenes with a 5/11/3-membered ring system 
is the lathyrane group. The hydrocarbon nucleus of casbene and its saturated analog, 
casbane, may be considered to be the biogenetic precursor of these diterpenes. They can 
contain an epoxy function between C-4 and C-15, or C-5 and C-6, and double bonds between 
C-5 and C-6 and/or C-12 and C-13. The configurations of the fusion of rings A and B are 
usually trans, while those of rings B and C have the cis configuration. 
Duarte et al. investigated the diterpene constituents of E. lagascae and isolated three 
new (latilagascenes D–F, 76–78) and one known (jolkinol B) lathyrane diterpenes. 
Latilagascene D and E (and A–C, isolated previously from the plant) were the first 
macrocyclic lathyrane diterpenes that displayed oxidation at C-16. Latilagascene F differs 
from jolkinol B in only one substituent: it contains a benzoyloxy group instead of 
cinnamoyloxy group at C-15.47 Wang et al. isolated two lathyrane diterpenes (61 and 62) 
from the ethanol extract of the roots of E. kansuensis. The roots of this plant have been used 
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in Tibetian medicine, as a cholagog and purgative and in cases of pyretolysis and 
apocenosis.48  
Jiao et al. isolated a new lathyrane diterpenoid (Euphorbia factor L8, 58) from the 
seeds of E. lathyris. Its absolute configuration was determined by single-crystal X-ray 
diffraction.49 This research group later isolated six lathyrane diterpenes from the seeds of E. 
lathyris: two of them new, [Euphorbia factor L7a (75) and L7b (63)], with jolkinol, isolathyrol, 
7-hydroxylathyrol and lathyrol. The 13C NMR and X-ray diffraction data of Euphorbia factor 
L7a (75) and L7b (63) were analyzed for the first time.
50 In 2011, Zhang et al. isolated 
Euphorbia factor L3 (60) from the ethanol extract of the seeds of this plant.
51 
Li et al. isolated 10 ingols (4,15-epoxylathyrane-type diterpenes) (90–99) from the 
aerial parts of E. royleana. This plant, which is a common thorny succulent occurring in 
south-western mainland China, is known in the traditional Chinese medicine as a fencing 
plant.52 
Feng et al. isolated a new lathyrane diterpene glucoside (105) from E. helioscopia. 
This was the first isolation of a glycosylated Euphorbia diterpene. To date, more than 30 
diterpenoids have been isolated from this plant.53  
A new lathyrane diterpene (89) was isolated from E. bungei by Shokoohinia et al.,44 
while Ayatollahi et al. isolated two new esters of 6(17)-epoxylathyrol (101 and 102) from the 
aerial parts of E. aellenii. This plant has been used in Iranian ethnopharmacology as a strong 
laxative, in the therapy of gout and for curing sores.54 Tian et al. isolated 17 new (59, 64–68, 
71–74, 78, 80–85) and 2 known (15β-O-benzoyl-5α-hydroxyisolathyrol and jolkinol A) 
lathyrane diterpenes from the ethanol extract of the roots of E. micractina.55 Avila et al. 
isolated two new diterpenes (69 and 70) from the ethyl acetate extract of the latex of E. 
laurifolia.56 In 2012, Xu et al. recently isolated 4 lathyrane diterpenes from E. prolifera, 
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including one new compound (103), and presented previously unreported spectroscopic 
data on another [(12E,2S,3S,4R,5R,6S,9S,11S,15R)-3-propionyloxy-5,15-diacetoxy-6,17-
epoxylathyra-12-en-14-one, 104].57 Finally, Toume et al. isolated an ingol diterpene (100) 
from the leaves of E. neriifolia, a perennial shrub whose leaves are used in traditional 
medicine as an aphrodisiac, diuretic and antitussive.58 
 
3.2.4. Myrsinanes, premyrsinanes and cyclomyrsinanes 
 
Myrsinane diterpenes are based on a 5/7/6-tricyclic ring system. The configurations 
of the fusion of rings A and B and rings B and C are trans. Ester groups are located mainly at 
C-3, C-5, C-7 and C-15, with a double bond between C-8 and C-9. Premyrsinanes have a 
5/7/6/3-tetracyclic, and cyclomyrsinanes a 5/7/6/4-tetracyclic carbon framework. In both 
cases, a hemiacetal ring or a 13/17-epoxy ring can be present. 
In 2009, Ayatollahi et al. isolated a myrsinane diterpene (decipinone, 121) from the 
aerial parts of E. splendida, found in the west of Iran.59 In the same year, they isolated two 
new 14-desoxo-10,18-dihydromyrsinols (106 and 107) from the cytotoxic chloroform 
fraction of E. aellenii. This type of diterpenoids is very rare in nature, and previously found 
only in E. prolifera.60 Li et al. isolated four new (proliferins A–D, 110–112 and 144) and four 
known (euphorprolitherin B and D, SPr5 and 14-desoxo-3-O-propionyl-5,15-di-O-acetyl-7-O-
nicotinoylmyrsinol 14β-acetate) myrsinol diterpenes from the ethanol extract of the roots of 
E. prolifera.61 Xu et al. isolated 10 new myrsinol diterpenoids (euphorbiaproliferins A–J, 125, 
126, 113, 114, 118–120, 140, 141 and 145) from the roots of E. prolifera. The structure of 
euphorbiaproliferin A was confirmed by X-ray crystallography.62 Later, Xu et al. isolated 10 
new compounds (euphorbialoids A–J, 122, 123, 108, 109, 131–134, 146, and 147) from the 
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methanol extract of the roots of the plant. The absolute configurations of two compounds 
(108 and 131) were determined by X-ray crystallography.63 Seven further compounds, 
euphorbialoids K–N (124, 138, 139 and 142) and 115–117 were also isolated from this 
plant.64,65 
In 2010, Shokoohinia et al. isolated four premyrsinane diterpenoids (127–130) from 
the aerial parts of E. macroclada.74 Sulyok et al. isolated four premyrsinane-type diterpenes 
(135–137 and 143) and two new (148 and 149) and one known (SPr4) cyclomyrsinane 
derivatives from the methanol extract of E. falcata.66,67 Compound 143 contains a rare 
hemiacetal moiety. Cyclomyrsinanes are hexa- and heptaesters of diterpene polyols, 
esterified with acetic, propanoic, 2-methylbutanoic or benzoic acids. 
 
3.2.5. Daphnanes 
 
Daphnane diterpenoids are based on a 5/7/6-tricyclic skeleton. The configurations of 
the fusions of rings A and B and rings B and C are trans. Most daphnane diterpenoids are 
polyhydroxy derivatives substituted at C-4, C-9 and C-20.17 C-3 forms a carbonyl group, and 
double bonds can be found in positions C-1/C-2 and C-6/C-7.17 
Wang et al. isolated a daphnane diterpenoid (150) from E. fischeriana.69 Yan et al. 
investigated the roots of E. fischeriana and isolated 17-acetoxyjolkinolide B, together with 
six known daphnanes. This herb has been used in traditional medicine for the treatment of 
cancer, edema and ascites.68 
 
3.2.6. Tiglianes 
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Tigliane diterpenoids have a 5/7/6/3-tetracyclic ring system. The configurations of 
the fusions of rings A and B are usually trans, while those of rings B and C are trans, and 
those of rings C and D have the cis configuration. Most tigliane diterpenoids contain hydroxy 
groups in C-4, C-9, C-13 and C-20 positions. C-3 forms a carbonyl group, and olefin bonds can 
be found between C-1 and C-2 and between C-6 and C-7.17 
A new tigliane diterpenoid (176) was described from the roots of E. fischeriana by 
Wang et al., and three known compounds were obtained for the first time from this plant, 
too.69 A phytochemical investigation of E. grandicornis herb resulted in the isolation of two 
new tigliane diterpenes (174 and 175). Their structures are rare, since the molecule contains 
a 5-en-7-one or 5-en-7-ol functionality instead of the usual 6,7-olefin group. The proposed 
biosynthesis of the compounds was also discussed (Scheme 1).70  
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Scheme 1. Proposed biogenesis of unusual tigliane diterpenes70 
 
Ghanadian et al. isolated two new diterpenoids (171 and 172) from the cytotoxic 
chloroform extract of E. aellenii,71 and Aljancic et al. isolated a new compound 
(euphodendriane A, 173) from E. dendroides.46 
E. cornigera is considered to be one of the most toxic species of the Euphorbiaceae 
family. On the other hand its shoots, roots, leaves and fruits are used for the treatment of 
various ailments in Pakistan. Baloch et al. studied the components of the roots of the plant 
and isolated nine new compounds (159–167), all of them were diesters of 13,20-O-diacyl -
12-deoxyphorbol.72 Later, the same group isolated eight new deoxyphorbol esters (151–158) 
from the fresh latex of E. cauducifolia, five of them substituted with the rare N-(2-
aminobenzoyl)anthraniloyl moiety.73 
From E. macroclada, three 4,12-dideoxy-(4αH)-phorbol analogs (168–170), differing 
only in the esterification pattern, and one A-seco-phorboid (177) were isolated by 
Shokoohinia et al.; A-seco-tigliane 177 is an unprecedented type of natural diterpenoids.74 
 
3.2.7. Ingenanes 
 
Ingenane diterpenoids have a 5/7/7/3-tetracyclic ring system including a ketone 
bridge between C-8 and C-10. A double bond can be found in ring A between C-1/C-2, and 
another between C-6/C-7 in ring B. Moreover, a β-hydroxy group is linked to C-4, and rings A 
and B are trans-fused.17 There may be an oxygen functionality (hydroxy, acetyl, benzoyl or 
long-chain alkyl ester) at some positions, e.g. C-3, C-5, C-13, C-17 and C-20.  
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In 2008, Lu et al. isolated 16 new ingenane diterpenoids (180–195) from the ethanol 
extract of E. esula.75 Later, Wang et al. isolated one new (179) and two known ingenanes 
from this plant.76 Li et al. investigated the compounds of E. kansui. The toxicity of this plant, 
which has long been known, could be greatly reduced by heating the plant with rice vinegar. 
Processed E. kansui was studied with the aim to survay its chemical constituents and a new 
diterpene (4-O-acetyl-5-O-benzoyl-3β-hydroxy-20-deoxyingenol, 178) was isolated.11 In the 
same year, Shi et al. isolated two new ingenanes (216 and 217) from the roots of this plant.77 
Baloch et al. isolated eight new ingenol derivatives (206–213) from the acetone 
extract of E. cornigera roots. Five of the compounds are esterified with the rare anthraniloyl 
group.78 They later isolated two new (214 and 215) and two known [3-O-(2,3-
dimethylbutanoyl)-13-O-dodecanoyl-20-O-hexadecanylingenol and 13-O-dodecanoyl-20-O-
hexanoylingenol] diterpenoids from the shoots of the plant.79 
In 2010, Baloch et al. isolated 10 new ingenane-type esters (196–205) from the latex 
of E. cauducifolia (syn. E. nerifolia). The diterpenes are substituted with acetyl, angeloyl, 
palmitoyl, tetradecatrienoyl or benzoyl groups.80 In the same year, Deng et al. isolated the 
known ingenol 3-myristate and ingenol 3-palmitate from E. ebracteolata. This plant is one of 
the sources of raw material for Langdu, which is commonly used in traditional Chinese 
medicine. The highly toxic roots of E. ebracteolata are often used to treat pulmonary 
tuberculosis, psoriasis, neuropathic dermatitis and chronic bronchitis.19 Moreover, Deng et 
al. isolated two known (ingenol 3-myristate and ingenol-3 palmitate) and two new ingenane 
diterpenes (218 and 219) from the roots of E. ebracteolata.19,81 
 
3.2.8. Paralianes and pepluanes 
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In 2007, two new (paralianone 220 and pepluene 221) and two known diterpenes 
were isolated by Barile et al. from E. paralias.82 Their structures demonstrated close analogy 
to that of pepluanone, isolated previously from E. peplus.83  
Table 2. Isolated compounds 
 
Compound R (common names) Plant Ref. 
Rosane    
 
 
1.  E. ebracteolata 81 
ent-Abietanes    
 
 
2.  E. neriifolia 27 
 
 
3.  E. formosana 23 
 
 
4.  E. formosana 23 
28 
 
 
5. retusolide A E. retusa 21 
 
 
6. R=H retusolide B 
7. R=OH retusolide D 
 
E. retusa 21 
 
 
8. retusolide C E. retusa 21 
 
 
9. retusolide E E. retusa 21 
 
 
10. retusolide F E. retusa 21 
 
 
11.  E. guyoniana 22 
29 
 
 
12.  E. guyoniana 22 
Atisanes and seco-atisanes 
 
   
 
 
13. R=CH2OH 
14. R=CH3 
 
E. neriifolia 27 
 
 
15.  E. neriifolia 27 
 
 
16. R=H 
17. R=CH3  
E. neriifolia 27 
ent-Kauranes and ent-seco-kauranes 
 
   
 
 
18.  E. hirta 26 
 
 
19.  E. neriifolia 27 
30 
 
 
20.  E. neriifolia 27 
Dimeric higher diterpenoids    
 
 
21. bisyinshanic acid A E. yinshanica 29 
 
 
22. bisyinshanic acid B E. yinshanica 29 
Casbane    
 
 
23. pekinenal E. pekinensis 10 
Jatrophanes    
31 
 
 
24. euphornin L E. helioscopia 34 
 
 
25. euphornin N E. helioscopia 35 
 
 
26. euphopeplin A E. peplus 45 
 
 
27. R1=Bz, R2=H, R3=Ac, R4=H, 
R5=Ac 
28. R1=Ac, R2=Ac, R3=iBu, R4=Bz, 
R5=H 
E. sororia 41 
 
 
29. R1=Nic, R2=Bz, R3=Ac, 
guyonianin C 
30. R1=Bz, R2=Ac, R3=Bz, 
euphotuckeyanol 
E. guyoniana 
 
E. tuckeyana 
5 
 
33 
 
 
 
31. guyonianin D E. guyoniana 5 
 
 
32. R1=Prop, R2=iBu, R3=Ac, 
R4=Nic, R5=H, 
euphodendrophane A 
33. R1=iBu, R2=iBu, R3=Ac, R4=Nic, 
R5=H, euphodendrophane B 
34. R1=Prop, R2=iBu, R3=Ac, 
R4=Nic, R5=Ac, 
E. dendroides 46 
32 
euphodendrophane C 
35. R1=iBu, R2=Ac, R3=Bz, R4=Ac, 
R5=H, euphodendrophane D 
36. R1=Prop, R2=iBu, R3=Bz, R4=Ac, 
R5=H, euphodendrophane E 
 
 
37. R1=Nic, R2=Ac 
38. R1=Nic, R2=iBu 
39. R1=Bz, R2=iBu 
40. R1=Bz, R2=Ac 
 
E. sororia 41 
 
 
41. R1=ONic, R2=Ac, esulatin K 
42. R1=OAc, R2=iBu, esulatin L 
43. R1=H, R2=iBu, esulatin M 
 
E. esula 43 
 
 
44. R=MeBu, tuckeyanol A 
45. R=iBu, tuckeyanol B 
 
E. tuckeyana 33 
 
 
46. R=H, guyonianin E 
47. R=OAc, guyonianin F 
 
E. guyoniana 32 
 
 
48. R1=OBz, R2=Ac, esulatin I 
49. R1=H, R2=iBu, esulatin J 
 
E. esula 43 
 
 
50. R=Ac 
51. R=Bz 
 
E. bungei 44 
33 
 
 
52. euphodendrophane F E. dendroides 46 
 
 
53. kansuinine J E. kansui 40 
 
 
54. esulatin H E. esula 43 
 
 
55. sororianolide A E. sororia 42 
 
 
56. sororianolide C E. sororia 42 
 
 
57. sororianolide B E. sororia 42 
Lathyranes    
34 
 
 
58. Euphorbia factor L8 E. lathyris 49 
 
 
59. R1=CH3, R
2=H, R3=Cinn 
60. R1=OBz, R2=Ac, R3=Ac, 
Euphorbia factor L3 
 
E. micractina 
E. lathyris 
55 
51 
 
 
61. R1=H, R2=Cinn 
62. R1=OH, R2=Cinn 
 
E. kansuensis 48 
 
 
63. Euphorbia factor L7b E. lathyris 50 
 
 
64. R1=Cinn, R2=H, R3=H 
65. R1=H, R2=H, R3=Cinn 
66. R1=Ac, R2=H, R3=Bz 
67. R1=H, R2=Ac, R3=Bz 
68. R1=ipropilidene, 
R2=ipropilidene, R3=Bz 
 
E. micractina 55 
 
 
69.  E. laurifolia 56 
 
 
70.  E. laurifolia 56 
 
71. R1=Ac, R2=Ac 
72. R1=Cinn, R2=H 
73. R1=H, R2=Cinn 
74. R1=H, R2=Bz 
E. micractina 55 
35 
  
 
 
75. Euphorbia factor L7a E. lathyris 50 
 
 
76. R=H, latilagascene D 
77. R=OH, latilagascene E 
E. lagasce 47 
 
 
78. R1=H, R2=Bz, latilagascene F 
79. R1=Ac, R2=Ac 
80. R1=Ac, R2=H 
81. R1=H, R2=Ac 
82. R1=Cinn, R2=H 
83. R1=Bz, R2=Bz 
84. R1=Bz, R2=H 
85. R1=Ac, R2=Bz 
 
E. lagasce 
 
E. micractina 
47 
 
55 
 
 
86. R1=Bz, R2=Ac, latilagascene G 
87. R1=Prop, R2=Prop, latilagascene 
H 
88. R1=Bu, R2=Bu, latilagascene I 
E. lagasce 47 
 
 
89.  E. bungei 44 
 
 
90. R=Bz 
91. R=Tig 
E. royleana 52 
 
92. R1=Tig, R2=H, R3=Tig 
93. R1=Tig, R2=Tig, R3=Ac 
94. R1=Tig, R2=Bz, R3=Tig 
95. R1=Bz, R2=Bz, R3=Ac 
96. R1=Ac, R2=Bz, R3=Ac 
97. R1=Tig, R2=H, R3=Bz 
E. royleana 52 
36 
98. R1=Bz, R2=H, R3=Bz 
99. R1=Bz, R2=H, R3=Tig 
 
 
100.  E. neriifolia 58 
 
 
101. R=Nic 
102. R=Ac 
 
E. aellenii 54 
 
 
103. R=Bu 
104. R=Prop 
E. prolifera 57 
 
 
105.  E. helioscopia 53 
Myrsinanes    
 
 
106. R=Bz 
107. R=Bu 
 
E. aellenii 60 
 
 
108. R1=Nic, R2=Prop, 
euphorbialoid I 
109. R1=iBu, R2=Nic, 
euphorbialoid J 
E. prolifera 63 
 
110. R=2-MeProp, proliferin A 
111. R=OBz, proliferin B 
112. R=H, proliferin C 
 
 
E. prolifera 61 
37 
 
 
113. R1=iBu, R2=Prop, R3=iBu, 
euphorbiaproliferin A 
114. R1=Bz, R2=Bu, R3=Bz, 
euphorbiaproliferin B 
115. R1=iBu, R2=Ac, R3=Bz 
116. R1=Bz, R2=Ac, R3=Bz 
117. R1=iBu, R2=Prop, R3=H 
 
E. prolifera 62 
 
 
 
 
 
65 
 
118. R1=Prop, R2=Ac, R3=Bz, 
euphorbiaproliferin F 
119. R1=Prop, R2=Ac, R3=Ac, 
euphorbiaproliferin G 
120. R1=Ac, R2=Bz, R3=Bz, 
euphorbiaproliferin H 
 
E. prolifera 62 
 
 
121. decipinone E. splendida 59 
 
 
122. R1=Nic, R2=Ac, euphorbialoid 
E 
123. R1=Prop, R2=Nic, 
euphorbialoid F 
124. R1=Ac, R2=Nic, euphorbialoid 
N 
125. R1=iBu, R2=Ac, 
euphorbiaproliferin C 
126. R1=Prop, R2=Bz, 
euphorbiaproliferin D 
 
E. prolifera 63 
 
63 
 
64 
 
62 
 
62 
 
Premyrsinanes    
 
 
127. R1=Bu, R2=Tig, R3=H 
128. R1=Prop, R2=Tig, R3=H 
129. R1=iBu, R2=Tig, R3=Ac 
130. R1=Bu, R2=MeBu, R3=Ac 
 
E. macroclada 74 
38 
 
 
131. R1=Prop, R2=H, euphorbialoid 
A 
132. R1=Ac, R2=H, euphorbialoid B 
133. R1=Prop, R2=Ac, 
euphorbialoid C 
134. R1=Bu, R2=Ac, euphorbialoid 
D 
 
E. prolifera 63 
 
 
135. R1=Hex, R2=H, R3=H, R4=H 
136. R1=Prop, R2=Ac, R3=OBz, 
R4=Ac 
137. R1=iBu, R2=H, R3=OBz, R4=Ac 
 
E. falcata 66 
 
 
138. R=Ac, euphorbialoid K 
139. R=Nic, euphorbialoid M 
E. prolifera 64 
 
 
140. R=Prop, euphorbiaproliferin I 
141. R=Bu, euphorbiaproliferin J 
E. prolifera 62 
 
 
142. euphorbialoid L E. prolifera 64 
 
 
143.  E. falcata 66 
Cyclomyrsinanes    
 
144. R=Prop, proliferin D 
145. R=Ac, euphorbiaproliferin E 
E. prolifera 61 
62 
39 
 
 
146. R1=Nic, R2=Ac, R3=H, 
euphorbialoid G 
147. R1=Bz, R2=Nic, R3=Ac, 
euphorbialoid H 
 
E. prolifera 63 
 
 
148. R=MeBu 
149. R=iBu 
 
E. falcata 67 
Daphnane    
 
 
150.  E. fischeriana 69 
Tiglianes and seco-tiglianes    
 
 
151. R1=Ang, R2=Ac 
152. R1=Ac, R2=Anth 
153. R1=Bz, R2=Bz 
154. R1=Ang, R2=Ang 
155. R1=Anth, R2=Ang 
156. R1=Anth, R2=Tig 
157. R1=Anth, R2=Bz 
158. R1=Anth, R2=Hex 
 
E. cauducifolia 73 
 
 
159. R1=Ac, R2=Bz 
160. R1=Ac, R2=p-methoxyBz 
161. R1=Dec, R2=Ang 
162. R1=Dec, R2=Tig 
163. R1=Ac, R2=Dec 
164. R1=Bu, R2=Dec 
165. R1=Hex, R2=Dec 
166. R1=Oct, R2=Dec 
167. R1=Dodec, R2=Dec 
 
E. cornigera 72 
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168. R1=CH2OAc, R
2=CH3 
169. R1=CH2OAc, R
2=H 
170. R1=CHO, R2=CH3 
 
E. macroclada 74 
 
 
171. R=H 
172. R=OH 
E. aellenii 71 
 
 
173. euphodendriane A E. dendroides 46 
 
 
174.  E. grandicornis 70 
 
 
175.  E. grandicornis 70 
 
 
176.  E. fischeriana 69 
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177.  E. macroclada 74 
Ingenanes    
 
 
178.  E. kansui 11 
 
 
179.  E. esula 76 
 
 
180. R1=A, R2=H, R3=OBz, R4=H 
181. R1=A, R2=H, R3=OBz, R4=OA 
182. R1=A, R2=OH, R3=OBz, R4=OA 
183. R1=H, R2=OA, R3=OBz, R4=OA 
184. R1=H, R2=OH, R3=OBz, 
R4=OOct 
185. R1=Bz, R2=OH, R3=OBz, 
R4=OOct 
186. R1=H, R2=OBz, R3=OBz, 
R4=OOct 
187. R1=Bz, R2=H, R3=OBz, 
R4=OOct 
188. R1=A, R2=OH, R3=OBz, 
R4=OOct 
189. R1=H, R2=OA, R3=OBz, 
R4=OOct 
190. R1=Bz, R2=OH, R3=OBz, 
R4=OBz 
191. R1=A, R2=OH, R3=OBz, 
R4=OBz 
192. R1=Bz, R2=OH, R3=OBz, 
R4=OA 
E. esula 75 
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193. R1=A, R2=H, R3=OBz, R4=OBz 
194. R1=Bz, R2=OH, R3=H, R4=OBz 
195. R1=A, R2=OH, R3=H, R4=OOct 
 
 
 
196. R1=Ang, R2=H, R3=H, R4=Palm 
197. R1=Palm, R2=Ang, R3=H, R4=H 
198. R1=H, R2=Ang, R3=H, R4=Palm 
199. R1=Ang, R2=Palm, R3=H, R4=H 
200. R1=H, R2=H, R3=Palm, 
R4=Tetradec 
201. R1=H, R2=Ang, R3=H, R4=Bz 
202. R1=H, R2=Ang, R3=Ac, R4=Ac 
203. R1=Ang, R2=H, R3=Ac, R4=Bz 
204. R1=Ac, R2=Ang, R3=H, R4=Bz 
205. R1=Ac, R2=Ang, R3=Ac, R4=Ac 
 
E. cauducifolia 80 
 
 
206. R1=N-(2-aminobenzoyl)anth, 
R2=Ac, R3=Ang 
207. R1=N-(2-aminobenzoyl)anth, 
R2=Ang, R3=Ac 
208. R1=Ac, R2=N-(2-
aminobenzoyl)anth, R3=Ang 
209. R1=Ac, R2=Ang, R3=N-(2-
aminobenzoyl)anth 
210. R1=Ang, R2=Ac, R3=N-(2-
aminobenzoyl)anth 
211. R1=Ang, R2=N-(2-
aminobenzoyl)anth, R3=Ac 
212. R1=Ac, R2=N-(2-
aminobenzoyl)anth, R3=Ac 
213. R1=N-(2-aminobenzoyl)anth, 
R2=Ac, R3=Ac 
 
E. cornigera 78 
 
 
214. R1=Bu, R2=Tet, R3=Dodec 
215. R1=Dec, R2=Hex, R3=H 
 
E. cornigera 79 
 
216. R=Dodec 
217. R=Dec 
E. kansui 77 
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218. R=Palm 
219. R=Tetradec 
 
E. ebracteolata 81 
Paraliane    
 
 
220. paralianone E. paralias 82 
Pepluane    
 
 
221. pepluene E. paralias 82 
 
Ester groups: Ac = acetyl, Bz = benzoyl, p-methoxyBz = p-methoxybenzoyl, Nic = nicotinoyl, 
Cinn = cinnamoyl, Anth = anthraniloyl, Tig = tigloyl, Prop = propanoyl, Bu = butanoyl, 
iBu = isobutanoyl, MeBu = 2-methylbutanoyl, A = 2,3-dimethylbutanoyl, 
iPent = isopentanoyl, iVal = isovaleroyl, Hex = hexanoyl, Ang = angeloyl, Oct = octanoyl, 
Dodec = dodecanoyl, Dec = decanoyl, Myr = myristoyl, Palm = palmitoyl, 
Tetradec = tetradecanoyl 
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4. Occurrence of Euphorbia diterpenoids 
 
To date, diterpenes have been isolated from 78 Euphorbia species (Table 3). In the 
last 5 years, the newly investigated plants were E. aellenii, E. bungei, E. falcata, E. 
formosana, E. grandicornis, E. hirta, E. laurifolia, E. macroclada, E. neriifolia, E. pekinensis, E. 
retusa, E. royleana, E. sororia, E. splendida, E. tuckeyana and E. yinshanica. Most of the 
diterpenes isolated from them are of the jatrophane type. Some species (E. caudicifolia, E. 
ebracteolata, E. fischeriana, E. guyoniana, E. helioscopia, E. neriifolia, E. portulacoides, E. 
pubescens, E. quinquecostata, E. segetalis, E. seguieriana, E. semiperfoliata, E. terracina and 
E. wallichii) contain both higher and lower diterpenes, while E. acaulis, E. calyptrata, E. 
characias, E. fidjiana, E. formosana, E. hirta, E. retusa, E. sessiliflora, E. sieboldiana and E. 
yinshanica synthesize only higher diterpenoids. The very high numbers of diterpenes 
isolated from E. prolifera (n=39), E. esula (n=36), E. kansui (n=32), E. cornigera (n=29) and E. 
cauducifolia (n=26) reflect the complexity of the mixtures of diterpenes that occur in plants 
of the Euphorbiaceae. There are some species (e.g. E. angulata, E. dentata, E. lucida, E. 
maculata, E. chamaesyce subsp. chamaesyce and E. davidii) in which the investigations have 
not revealed diterpenes, and the chemical screening of others (e.g. E. hirta, E. amygdaloides, 
E. epithymoides, E. palustris, E. pannonica, E. virgata, E. abyssinica and E. grandidens) has 
indicated only low quantities of diterpenes.7 
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Table 3. Occurrence of diterpenes in Euphorbiaceae species 
 
Species Types of diterpenes* Ref. 
E. acaulis ent-abietane (n=1) 6 
E. acrurensis lathyrane (n=9), ingenane (n=2) 6 
E. aellenii lathyrane (101, 102), myrsinane (106, 107), tigliane 
(171, 172) 
54, 60, 
71 
E. aleppica premyrsinane (n=4) 6 
E. altotibetic jatrophane (n=4) 6 
E. amygdaloides jatrophane (n=12) 6 
E. boetica premyrsinane (n=1) 6 
E. bungei jatrophane (50, 51), lathyrane (89) 44 
E. canariensis ingenane (n=3) 6 
E. caudicifolia ent-abietane (n=1), tigliane (151–158), ingenane 
(n=7) (196–205)  
6, 73, 
80 
E. calyptrata ent-abietane (n=2) 6 
E. characias ent-abietane (n=4), ent-atisane (n=3), ent-kaurane 
(n=1), ent-pimarane (n=3) 
6 
E. cheiradenia myrsinane (n=3) 6 
E. cornigera tigliane (n=10) (159–167), ingenane (206–215) 6, 72, 
78, 79 
E. cyparissias ingenane (n=2) 6 
E. decipiens myrsinane (n=20), premyrsinane (n=4) 6 
E. dendroides jatrophane (n=21) (32–36, 52), tigliane (173) 6, 46 
E. ebracteolata ent-abietane (n=3), rosane (1), casbane (n=2), 
ingenane (218, 219) 
6, 81 
E. esula jatrophane (n=5) (41–43, 48, 49, 54), ingenane 
(n=16), (179–195) 
6, 43, 
75, 76 
E. falcata premyrsinane (135–137, 143), cyclomyrsinane (148, 
149149) 
66, 67 
E. fidjiana ent-abietane (n=1), ent-atisane (n=6) 6 
E. fischeriana ent-abietane (n=9), ent-pimarane (n=1), dimer (n=2), 
other higher diterpenoids (n=1), daphnane (n=1) 
(150), tigliane (n=5) (176) 
6, 69 
E. formosana ent-abietane (3, 4) 23 
E. grandicornis tigliane (174, 175) 70 
E. guyoniana rosane (12), ent-abietane (11), jatrophane (29, 31, 
46, 47), tigliane (n=1) 
22, 5, 
32, 6 
E. helioscopia ent-abietane (n=5), jatrophane (n=5) (24, 25), 
lathyrane (105) 
6, 34, 
35, 53 
E. hermentiana lathyrane (n=2), ingenane (n=1) 6 
E. hirta ent-kaurane (18) 26 
E. hyberna jatrophane (n=1), lathyrane (n=2) 6 
E. hyberna subsp. insularis jatrophane (n=1) 6 
E. ingens lathyrane (n=1) 6 
46 
E. kamerunica lathyrane (n=1) 6 
E. kansuensis lathyrane (n=2) (61, 62) 6, 48 
E. kansui jatrophane (n=8) (53), ingenane (n=20) (178, 216, 
217) 
6, 40, 
11, 77 
E. lactea lathyrane (n=1) 6 
E. lagasce jatropholane (n=2), lathyrane (76–78, 86–88) 6, 47 
E. lathyris lathyrane (n=10) (58, 60, 63, 75), ingenane (n=4) 6, 49, 
50, 51 
E. laurifolia lathyrane (69, 70) 56 
E. leuconeura ingenane (n=1) 6 
E. macroclada premyrsinane (127–130), tigliane (168–170, 177) 74 
E. micractina lathyrane (59, 64–68, 71–74, 78, 80–85), 
euphoractine (n=5) 
6, 55 
E. mongolica jatrophane (n=3) 6 
E. myrsinites myrsinane (n=4) 6 
E. neriifolia ent-abietane (2), ent-atisane (13–17), ent-kaurane 
(19, 20), lathyrane (100) 
27, 58 
E. nivulia lathyrane (n=8) 6 
E. obtusifolia jatrophane (n=7), tigliane (n=6) 6 
E. officinarum lathyrane (n=3) 6 
E. paralias jatrophane (n=7), ingenane (n=2), segetane (n=12), 
paraliane (n=2) (220), pepluane (221) 
6, 82 
E. pekinensis casbane (23) 10 
E. peplus jatrophane (n=12) (26), ingenane (n=2), pepluane 
(n=3) 
6, 45 
E. pithyusa subsp. cupanii lathyrane (n=2), premyrsinane (n=7), tigliane (n=3) 6 
E. platyphyllos jatrophane (n=4) 6 
E. poisonii lathyrane (n=3), daphnane (n=2), tigliane (n=4) 6 
E. portlandica segetane (n=1) 6 
E. portulacoides ent-abietane (n=5), ent-kaurane (n=2), lathyrane 
(n=4), ingenane (n=1) 
6 
E. prolifera lathyrane (103, 104), myrsinane (n=4) (108–126), 
premyrsinane (131–134, 138–142) cyclomyrsinane 
(n=2) (144–147) 
6, 57, 
61, 62, 
63, 64 
E. pubescens ent-abietane (n=2), jatrophane (n=5) 6 
E. quinquecostata ent-atisane (n=2), ent-isopimarane (n=1), ingenane 
(n=2) 
6 
E. resinifera daphnane (n=1), tigliane (n=2), ingenane (n=1) 6 
E. retusa ent-atisane (5–10) 21 
E. royleana lathyrane (90–99) 52 
E. salicifolia jatrophane (n=6) 6 
E. segetalis other higher diterpene (n=1), jatrophane (n=15), 
lathyrane (n=1), ingenane (n=4), segetane (n=4), 
paraliane (n=4), pepluane (n=1) 
6 
E. seguieriana ent-abietane (n=4), jatrophane (n=1), myrsinane 
(n=7), cyclomyrsinane (n=2), premyrsinane (n=1) 
6 
47 
E. semiperfoliata ent-abietane (n=3), jatrophane (n=18), tigliane (n=2) 6 
E. serrulata jatrophane (n=13) 6 
E. sessiliflora ent-abietane (n=3) 6 
E. sieboldiana ent-kaurane (n=1) 6 
E. sororia jatrophane (27, 28, 37–40, 55–57) 41, 42 
E. splendida myrsinane (121) 59 
E. teheranica cyclomyrsinane (n=2) 6 
E. terracina ent-abietane (n=1), jatrophane (n=25) 6 
E. tirucally lathyrane (n=1) 6 
E. tuckeyana jatrophane (44, 45) 33 
E. turzaninowii jatrophane (n=6) 6 
E. villosa lathyrane (n=1), euphoractine (n=3) 6 
E. wallichii ent-trachylobane (n=3), ent-kaurane (n=1), ingenane 
(n=2) 
6 
E. yinshanica dimeric higher diterpenoid (21, 22) 29 
*n=number of previously reviewed compounds; or compounds according to the numbering 
in the present review 
 
5. Biological acitivities 
 
Compounds isolated from different Euphorbia species exert many different activities, 
including antiproliferative, MDR-reversing, antimicrobial, vasoactive, immunomodulatory 
and anti-inflammatory effects. 
 
5.1. Antitumor activity 
 
In the past few years, many investigations have been performed on the antitumor 
activity of Euphorbia diterpenes. Compounds with different skeletal types (e.g. casbane, 
abietane, ingenane, tigliane, lathyrane, myrsinane and jatrophane) proved to have moderate 
or strong antiproliferative effects on different human cancer cell lines (e.g. chronic myeloid 
leukaemia, nasopharyngeal, gastric, pancreatic, lung, ovarian and colon carcinomas). Some 
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of them were reported to have cytotoxic activity, others inducing apoptosis. The 
mechanisms of actions were also investigated in some cases, and it was observed that 
diterpenes could be cytotoxic via inhibition of the activity of topoisomerase II and/or DNA 
synthesis or protein kinase C (PKC) modulation or the induction of apoptosis through either 
the inhibition of IL-6-induced and STAT3 activation or inhibition of the NF-κB signalling 
pathway. 
Miyata et al. investigated the effects of ingenol diterpenes isolated from the roots of 
E. kansui on the proliferation activity of Xenopus embryo cells. Eight of the 20 investigated 
diterpenes [20-O-(2’E,4’E)-ingenol, 20-O-(2’E,4’Z)-ingenol, 3-O-(2’E,4’Z)-ingenol, 3-O-
(2’E,4’E)-ingenol, 20-O-(decanoyl)-ingenol, 5-O-(2’E,4’E)-ingenol, 5-O-benzoyl-20-
deoxyingenol and 3-O-(2’E,4’E-decadienoyl)-20-deoxyingenol] induced significant inhibition 
of cellular proliferation at low concentration. Further, it was stated that most of the 
diterpenes that inhibited cellular proliferation also inhibited topoisomerase II activity, since 
the high potency on topoisomerase II were measured.84 Later, Yoshida et al. studied the 
mechanism of inhibition of topoisomerase II activity and effects on the cell proliferation 
through DNA damage or the blockade of topoisomerase II by 20-O-(2’E,4’Z-decadienoyl)-
ingenol and 3-O-(2’E,4’Z-decadienoyl)-ingenol. The conclusion was drawn that 20-O-(2’E,4’Z-
decadienoyl)-ingenol is a catalytic inhibitor of topoisomerase II. It brought about the growth 
arrest of mouse mammary tumor (MMT) cells in the G2/M phase of the cell cycle, without 
inducing γ-H2AX by DNA breaks.85 
Luo et al. tested the cytotoxicity of jolkinolide B in human chronic myeloid leukaemia 
(K562), and observed that this compound displayed high activity against K562 cells, with an 
IC50 of 12.1 µg/mL.
86 Later, Wang et al. investigated the molecular mechanism of the 
antitumor effect of jolkinolide B.87 It was found that jolkinolide B treatment resulted in the 
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activation of caspase-3 and -9. Moreover, the compound reduced cell viability and induced 
apoptosis in a dose- and time-dependent manner in human leukaemic cells (U937). The 
induction of apoptosis was accompained by the downregulation of PI3K/Akt and the 
inhibition of apoptosis of protein family.88 
The in vitro antiproliferative activities of helioscopinolide E and B, isolated from E. 
tuckeyana, were investigated by Duarte et al. against human gastrointestinal cancer cell 
lines: gastric (EPG85-257), pancreatic (EPP85-181) and colon (HT-29) carcinomas. These 
compounds were inactive (IC50 = 108 ± 3 µM in case of helioscopinolide E and 
IC50 = 102 ± 3 µM in case of helioscopinolide B) against the colon carcinoma cell line (HT-29) 
and showed moderate growth inhibitory activity on the gastric (EPG85-257) (IC50 = 45 ± 4 µM 
in case of helioscopinolide E and IC50 = 38 ± 2 µM in case of helioscopinolide B) and 
pancreatic (EPP85-181) (IC50 = 45 ± 4 µM for helioscopinolide E and IC50 = 38 ± 2 µM for 
helioscopinolide B) tumor cells.33 
The antitumor activities of 12-deoxyphorbol esters isolated from E. cornigera were 
investigated by Baloch et al. Three compounds (166, 167 and 13,20-didecanoylphorbol) were 
cytotoxic, and displayed IC50 values of 0.8, 0.5 and 1.0 µg/mL, respectively. The mechanisms 
of their action in the inhibition of DNA synthesis were also investigated and a significant 
correlation was found between the cytotoxicity and DNA cross-link and DNA strand-break 
formation.72 The levels of in vitro cytotoxicity of 4 ingenol derivatives (214, 215, 3-O-(2,3-
dimethylbutanoyl)-13-O-dodecanoyl-20-O-hexadecanoylingenol and 13-O-dodecanoyl-20-O-
hexanoylingenol) isolated from E. cornigera were evaluated against RAW (mouse 
macrophage cells) and HT-29 (a colon cancer cell line) by the same group, using the MTT [3-
(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assay. Compound 214 displayed 
noteworthy cytotoxicity, with IC50 = 5.0 μM (RAW) and 2.90 μM (HT-29). It was 5- and 1.5-
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fold more effective against RAW and HT-29 cancer cell lines than the positive control 
amrubicin hydrochloride [IC50 = 25.0 μM (RAW) and 4.36 μM (HT-29)]. Compound 215 
showed moderate cytotoxic activity against both cell lines [IC50 = 10.0 μM (RAW) and 10.0 
μM (HT-29)].79 
It is well-known that most chemotherapeutic agents exert their anticancer activity by 
inducing apoptosis or programmed cell death.47 Resistance to apoptosis may be a major 
factor for the ineffectiveness of cancer treatment. Investigation of the apoptosis-inducing 
mechanism of 17-hydroxyjolkinolide B (HJB) revealed that HJB strongly inhibits IL-6-induced 
and constitutive STAT3 (signal transducer and activator of transcription) activation. 
Furthermore, HJB directly targets the JAK (Janus kinase) family kinases, JAK1, JAK2, and 
TYK2, by inducing dimerization of the JAKs via cross-linking. HJB has no activity on the 
platelet-derived and epidermal growth factor, or insulin-like growth factor 1 signalling 
pathways, therefore its effect is highly specific.89 
Yan et al. investigated the antitumor effects of 17-acetoxyjolkinolide B and 6 
analogues, isolated from E. fischeriana. It was concluded that these compounds irreversibly 
inhibit the NF-κB signalling pathway by interacting directly with inhibitory kappa B kinases 
(IKK-β). Moreover, 17-acetoxyjolkinolide B induces apoptosis of tumor cells and acts 
synergistically with anticancer drugs such as doxorubicin.68 
Serova et al. investigated the effects of PKC modulation by ingenol 3-angelate 
(PEP005, ingenol mebutate) on mitogen-activated protein kinase and phosphatidylinositol 3-
kinase signalling in cancer cells, and concluded that both the AKT (also known as protein 
kinase B) and Ras/Raf/MAPK pathways in Colo205 colon cancer cells are differentially 
modulated by ingenol 3-angelate, and that only the latter is mediated by PKC isozymes.90 
Ersvaer et al. later evaluated the balance between the efficacy and toxicity of ingenol 3-
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angelate in the treatment of human cancer. This hydrophobic diterpene ester is a selective 
activator of PKC 10–100 at concentrations of ng/mL, but strongly cytotoxic at high 
concentration (100 μg/mL).91,92 Ingenol 3-angelate has both anticancer and proinflammatory 
effects, which is an advantage in topical skin application, but it can be dangerous in the 
event of systemic therapy. In conclusion, the authors established that extensive in vivo 
experimental models and carefully designed clinical studies can clarify whether the systemic 
use of this compound will be acceptable with regard to the risk of toxicity.93 
Tao et al. investigated the cytotoxic activity of jatrophane diterpenes, isolated from E. 
helioscopia, on HL-60 cells by the MTT method and on A-549 cells by the SRB 
(sulphorhodamine B) method. Two compounds [euphornin L (24) and euphoscopin F] 
exhibited cytotoxicity against HL-60, with IC50 values of 2.7 and 9.0 µM, respectively, while 
the other compounds were inactive.34 Guyonianins E (46) and F (47) and 5,7,14-triacetoxy-3-
benzoyloxy-15-hydroxy-9-oxojatropha-6(17),11E-diene isolated from E. guyoniana were 
investigated for cytotoxic activity by Hegazy et al. 5,7,14-Triacetoxy-3-benzoyloxy-15-
hydroxy-9-oxojatropha-6(17),11E-diene exhibited significant activity (IC50 = 35 μM), and 
guyonianins E (46) and F (47) showed moderate activity (IC50 = 70 and 100 μM, respectively) 
against human embryonic kidney 293 (HEK293) cells.32 Investigation of the anticancer 
characteristics of euphodendrophane A (32) and B (33) on a sensitive non-small cell lung 
cancer cell line (NCI-H460) and its resistant counterpart (NCI-H460/R) demonstrated that 
these compounds inhibited the growth of these cancer cells (IC50 ≈ 20 µM for 33 and 
IC50 ≈ 50 µM for euphodendrophane 32, on both cell lines) and were non-toxic for peripheral 
blood mononuclear cells (PBMS). The effects of these compounds in combination with 
paclitaxel (PTX) were also examined.94 Jatrophanes overcome PTX resistance in 
concentration-dependent manner in multidrug resistant cancer cells (the strongest decrease 
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was observed in combination of 5 µM euphodendrophane A/B + 40 nM PTX), as these 
compounds induce cell killing and modify cell cycle distribution leading to G2/M arrest. The 
most pronounced effect was obtained with euphodendrophane B + PTX (40.4%). In addition, 
jatrophanes acts as anti-angiogenic agents by decreasing the vascular endothelial growth 
factor (VEGF) secretion (combination of euphodendrophane A with PTX exerted the 
strongest inhibition of VEGF secretion: 370 µg/mL).94 
Jatrophane diterpenes (41–43, 48, 49, 54, 2α,3β,5α,7β,15β-pentaacetoxy-9α-
nicotinoyloxyjatropha-6(17),11-dien-14-one, salicinolide and euphosalicin) isolated from E. 
esula were investigated for their antiproliferative activities by Vasas et al.43 It was 
demonstrated that the diterpenes possess tumor cell growth-inhibitory activities on HeLa 
(cervix adenocarcinoma), Ishikawa (endometrial adenocarcinoma), and MCF7 (breast 
epithelial adenocarcinoma) cells. Esulatins J (49), A, and E exhibited the highest activities 
against all three cell lines; especially esulatin J (49) displayed high antiproliferative effect on 
Ishikawa (98.4%) and MCF7 (81.4%) cells at the tested concentration 30 μg/mL.43 
The cytotoxic activity of pekinenal (23) was investigated against 4 human cancer cell 
lines, NCI-H460 (lung), KB (nasopharyngeal), SGC7901 (gastric) and HO-8910 (ovarian), by the 
MTT assay. The compound exhibited cytotoxic activity, with IC50 values of 10.05, 8.52, 13.82, 
and 14.16 µg/mL, respectively.10 Wang et al. evaluated the cytotoxicities of 6 tigliane-type 
diterpenes (150, 176 and four known ones) isolated from E. fischeriana against human 
cancer cell lines, MDA-MB-231 and HepG2, and a human immortalized cell line (HEK293). 
Only 12-deoxyphorbol 13-hexadecanoate was found to be cytotoxic against MDA-MB-231 
cells (IC50 = 6.694 μM).
69 In the following year, Zhang et al. investigated the antiproliferative 
activity of euphorbia factor L3 (60) against a lung cancer cell line (A549) in vitro. It was stated 
that this compound has high cytotoxic effect and induce apoptosis via the mitochondrial 
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pathway in A549 cells, with involvement of the loss of mitochondrial potential and the 
release of cytochrome C.51 The cytotoxicities of proliferins A (110), B (111) and D (144), 
isolated from E. prolifera, were evaluated against various cancer cells (HCT-8, Bel-7402, BGC-
823, A549 and A2780). Only proliferin A (110) proved to be cytotoxic against A2780 human 
ovarian cancer cells (IC50 = 7.7 μM).
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The antiproliferative activity of premyrsinane (135–137, 143) and cyclomyrsinane 
(148, 149 and SPr4) diterpenes isolated from E. falcata were tested on HeLa, Ishikawa, and 
MCF7 cells, and for their ability to modulate resistance to doxorubicin in L5178 mouse 
lymphoma cells that over-express the MDR1 efflux pump.67 All compounds exhibited weak 
or moderate antiproliferative activities against all of the tested cell lines, only compound 137 
showed significant activity at the higher tested concentration (30 μg/mL). However all 
premyrsinane and cyclomyrsinane diterpenes proved to have a mild to a very strong 
synergism with doxorubicin against the MDR mouse lymphoma cell line.67 
Human cytomegalovirus (CMV) promotes tumor cell survival by inhibiting apoptosis, 
interfering with both the intrinsic and the extrinsic cellular apoptosis pathways CMV 
immediate-early (IE) antigen, accumulating in tumor tissues, and may provoke tumor 
promotion and progression.95 The development of strategies intended to inhibit the human 
CMV IE antigen expression and/or function is an important goal as concerns the prevention 
and treatment of certain forms of cancers associated with human CMV. Pusztai et al. 
investigated the effects of the lathyrane-type latilagascenes A, B, C, D (76) and E (77) and 
jolkinol B on CMV IE antigen expression in lung cancer cells. It was concluded that 
latilagascene E (77) demonstrated the highest activity, while latilagascene D (76) was 
inactive.95 
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5.2. Multidrug-resistance reversing activity 
 
The most common tumors are resistant to available drugs. One of the reasons of this 
is the multidrug resistance (MDR) of cancer cells which can be evolve by multiple 
mechanisms, e.g. with the expression of P-glycoprotein (P-gp, an efflux protein belonging to 
the ABC transporter superfamily) which transports anticancer drugs out of the cells. 
Therefore, inhibition of P-gp represents a promising approach for overcoming MDR. 
Compounds with a broad structural diversity can reverse P-gp mediated MDR.47 One group 
of them is the diterpenes, isolated from different Euphorbia species. Unfortunately, the 
knowledge on the mechanism of action, on a molecular basis, is still missing. The structure-
activity relationship studies concerning MDR reversing activity confirmed that 
hydrophobicity and the presence of hydrogen bond-acceptor groups in the molecules are 
important features for the interaction of the modulator with P-gp.96 Some P-gp modulators, 
such as verapamil and cyclosporine, also inhibit drug efflux in a competitive manner, 
whereas recent studies suggested an allosteric mode of action for several compounds.97 
 Jiao et al. investigated the MDR activities of six related lathyrane diterpenes (among 
them the new 63 and 75) isolated from E. lathyris on MCR7/ADM cell lines in vitro.50 The 
compounds contain jokinol, isolathyrol, 7-hydroxylathyrol, epoxylathyrol and lathyrol 
skeleton. The most active compounds were Euphorbia factor L7a (75) (reversal fold, 
RF = 10.33) and Euphorbia factor L2 (RF = 12.84) in comparison with the standard verapamil 
(RF = 2.95). It was established that the position of the double bond between C-6 and C-7, 
and substitution on C-7 are important factors relating to the capability of inhibition. The 
approximate sequence of various skeletons as MDR modulators was 7-hydroxylathyrol, 
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jokinol > lathyrol > epoxylathyrol > isolathyrol. None of the compounds showed significant 
cytotoxicity on MCF-7 cells.50 
Duarte et al. derivatized latilagascene B, previously isolated from E. lagasce, to yield 3 
new lathyrane esters: latilagascene G (86), H (87) and I (88)98. Their MDR-inhibitory activities 
were investigated together with those of tuckeyanols A and B, euphotuckeyanol, 
latilagascene A–F and jolkinol B. Structure–activity relationship studies were also carried out. 
It was stated that the most active lathyrane derivatives [86—88, fluorescence activity ratio 
(FAR) = 68.9, 61.6 and 62.4 at 4  µg/mL] has an aromatic ring at C-16, while replacement of 
the aromatic ring by an acetyl group at this position resulted in a decrease of activity 
(FAR = 13.0 and 12.2 for latilagascene A and C at 4 µg/mL). Moreover, 86 has a much lower 
FAR value than found for latilagascene D (76, FAR = 168.5 at 4.0 µg/mL) differing the two 
compounds only in the presence of a free hydroxyl group at C-3 in 76. In case of jatrophane 
polyesters euphotuckeyanol proved to be the most active (FAR = 81.0 at 4 µg/mL). This 
compound, with seven ester groups has the highest molecular weight (818), logP values 
(6.7), and the number of hydrogen bond acceptor groups is 15, all of them considered as 
important requirements to P-gp modulation. They investigated the antiproliferative effects 
of lathyranes and jatrophanes in combination with epirubicine on human MDR1 gene-
transfected mouse lymphoma cells, and found that all the tested diterpenes have a 
synergistic interaction with epirubicine on the studied cell line, the most effective were 87 
and euphotuckeyanol [fractional inhibitory index (FIX) = 0.07 (87) and 0.08 
(euphotuckeyanol), respectively].98 Later, the MDR-reversing and apoptosis-inducing 
activities of latilagascenes A–F [D (76) E (77) and F (78)] and jolkinol isolated from E. 
lagascae were evaluated. All the tested compounds exhibited drug retention enhancing 
activity by inhibiting the P-gp-mediated efflux-pump activity. Latilagascene E (77) displayed 
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the highest effect (FAR = 216.8, at 4 µg/mL). Moreover, the anti-MDR effect of latilagascene 
B in combination with doxorubicin on human MDR1 gene-transfected mouse lymphoma cells 
was also investigated in vitro. A synergistic interaction was observed between the two 
compounds (fractional inhibitory index (FIX) = 0.292). In the case of apoptosis induction, it 
was found that latilagascene B was the most active at the highest concentration.47 Lage et al. 
also investigated macrocyclic diterpenes [latilagascenes B, C and D (76), jolkinol B, ent-16α-
hydroxyatisane-3-one and ent-16α,17-dihydroxykauran-3-one] isolated from E. lagasce, and 
helioscopinolides A, B, D and E from E. tuckeyana, an acetylation reaction product of 
helioscopinolide B99 and acetylation products of ent-16α-hydroxatisane-3-one and ent-
16α,17-dihydroxykauran-3-one100) for their potential antineoplastic activity on gastric 
(EPG85-257), pancreatic (EPP85-181) and colon (HT-29) human carcinoma cell lines. 
Furthermore, the effects of these diterpenes on different multidrug-resistant variants of 
these cancer cell lines over-expressing MDR1/P-gp or without MDR1/P-gp expression were 
also evaluated. The most active compounds were the lathyrane diterpenes latilagascenes C 
(IC50 = 1.5 µM) and D (76) (IC50 = 2.7 µM), and the diterpene lactones helioscopinolide B 
(IC50 = 5.7 µM), 3β-acetoxyhelioscopinolide B (IC50 = 4.6 µM) and helioscopinolide E 
(IC50 = 4.4 µM), which exhibited high antineoplastic activities against the drug-resistant 
EPG85-257 cell line (etoposide was the positive control with IC50 = 6.2 µM).
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In the search for MDR-reversing compounds from natural sources, a series (n = 32) of 
Euphorbia diterpenes were tested by Molnár et al. on mouse lymphoma cells, using the 
rhodamine 123 exclusion test. The diterpenes investigated represented various skeletal 
types, e.g. jatrophanes, lathyranes and ’euphoractine-type’ compounds. The results showed 
that structurally different diterpene polyesters may display significant MDR-reversal 
effects.101 In another screening programme, Corea et al. investigated the MDR-modulatory 
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activities of 62 diterpenes isolated previously from Euphorbia species (E. dendroides, E. 
characias, E. peplus, E. paralias and E. helioscopia). Since these compounds were based on a 
structurally homogeneous skeleton, with differences only in the substitution pattern, a 
structure–activity relationship study was possible. Among others, it was concluded that the 
presence of hydroxy groups on C-3 and C-15, acetyl groups on C-8 and C-9 and a keto group 
on C-14 in jatrophanes increased the anti-MDR activity, while the presence of a hydroxy 
group on C-2, an acetyl group on C-14, and nicotinoyl groups on C-5 and C-9 reduced the 
inhibitory potency of the compounds.102 Jatrophane polyesters isolated from E. esula were 
assayed for their anti-MDR activity on L5178 mouse lymphoma cells. It was observed that 
the diterpenes differ significantly in the inhibition of the efflux pump activity of P-gp in 
tumor cells. Esulatin J (49) (FAR = 52.5 at 40 μg/mL) and esulatin M (43) (FAR = 119.9 at 40 
μg/mL) were found to be the most effective inhibitors of efflux pump acitivity.43 
In 2011, Zhang et al. investigated the MDR-reversing potency and the detailed 
mechanisms of actions of Euphorbia factor L1. It was concluded that this compound 
potentiated the sensitivity of the ABCB1 (ATP-binding cassette sub-family B member 1) 
substrates investigated and increased the accumulation of doxorubicin and rhodamine 123 
in ABCB1-mediated MDR KBv200 and MCF7/adr cells. Moreover, Euphorbia factor L1 did not 
downregulate the expression of ABCB1 at either an mRNA or a protein level.103 
The MMP-2 and -9 (matrix metalloprotein)-modulating activities of diterpenes 
isolated from E. formosana on human fibrosarcoma cell line HT1080 were investigated by Yu 
et al. Among them, 3-hydroxy-ent-abietane compounds [helioscopinolide A–C and ent-
(5β,8α,9β,10α,12α)-12-hydroxyatis-16-ene-3,14-dione)] significantly up-regulated the 
expressions of MMP-2 and -9 at concentrations of 10 and 50 µM.23 
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The purpose of the work of Ferreira et al. was to define an improved pharmacophore 
that combines the structural features of macrocycle diterpenes with the majority of 
compounds known to possess MDR inhibitory effect.104 In the course of the study a database 
containing 272 molecules with the ability to modulate the P-gp was used. It was stated that 
the mode of interaction with the transporter is principally hydrophobic, where the aromatic 
acceptor or donor groups are responsible for the increased affinity. The proposed 4-point 
pharmacophore comprised one hydrogen bond and three hydrophobic acceptor points.104 
Barile et al. performed structure-activity relationship studies on over sixty 
jatrophane, modified jatrophane, segetane, pepluane and paraliane diterpenoids isolated 
previously from Euphorbia dendroides, E. characias, E. peplus, E. amygdaloides and E. 
paralias. They focused on the anti-MDR and anti-inflammatory activities of the 
compounds.105 It was concluded that in case of euphodendroidins a free OH group at C-3, 
together with the negative effect of this group at C-2 were needed for the anti-MDR activity. 
Moreover, substitution at C-5 with an aromatic group (e.g. nicotinoyl) decreased the activity. 
The pharmacological evaluation of terracinolides and abeojatrophanes demonstrated the 
effect of substitution at positions C-3, C-6, and C-15, and the significance of the relative 
configuration of the free OH group, quite apart from its position. Euphocharacin derivatives 
are highlighting the positive roles of benzoyl and propyl groups at C-9 and C-3, respectively, 
and confirming the positive effect of hydroxyl group at C-15 and the negative role of the 
same group at C-2. Finally, in case of pepluane series investigated, pepluanin A with acetyl 
group at C-8 and nicotinoyl group at C-9 was found to be the most potent inhibitor of P-
gp.105 
 
5.3. Immunomodulatory activity 
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The immunomodulatory effect of 14-desoxo-3β,5α,7β,10,15β-O-pentaacetyl-14α-O-
benzoyl-10,18-dihydromyrsinol (106) isolated from E. aellenii was investigated on the 
oxidative burst activity of whole-blood phagocytes and the proliferation of human peripheral 
blood lymphocytes. In concentrations of 0.5, 5 and 50 μg/mL, 106 exhibited in the dose-
dependent suppression of T-cell proliferation by 39 ± 5.0%, 68 ± 2.0%, and 72 ± 1.6%, 
respectively.60 Later, the immunomodulating potentials of tigliane diterpenes (171 and 172) 
isolated from E. aellenii were tested by Ghanadian et al., using neutrophils of human whole 
blood. It was concluded that 4-deoxy-4αH-phorbol-12 (2,3-dimethyl)butyrate 13-isobutyrate 
(171) exhibited moderate inhibitory activity against both T-cell proliferation and reactive 
oxygen species production, with IC50 = 14 and 44.1 μg/mL, respectively.
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The in vitro anti-inflammatory activities of jolkinolides (jolkinolide A and B, and 17-
hydroxy-jolkinolide A and B) in lipopolysaccharide-stimulated RAW264 macrophages were 
investigated by Uto et al. Among them, 17-hydroxyjolkinolide B (HJB) was found to be the 
most powerful inhibitor of the LPS-induced production of inflammatory mediators such as 
NO, PGE2, and pro-inflammatory cytokines TNF-α and IL-6. These inhibitory effects were 
induced by the suppression of MAPK (mitogen-activated protein kinase) phosphorylation 
and NF-κB activation. Moreover, HJB was found to be a strong inducer of heme oxygenase-1 
protein and mRNA expression.106 
 
5.4. Anti-inflammatory activity 
 
Pepluanone, a diterpene component of E. peplus, possesses a high anti-inflammatory 
effect in vivo.107 In vitro assays of the compound on LPS-stimulated J774 murine 
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macrophages revealed that it decreased the production of PGE2, NO and TNF-α by 
decreasing the expression of iNOS, COX-2 and TNF-α mRNA, respectively.107 Barile et al. 
tested the anti-inflammatory activities of compounds (220 and 221) with pepluane and 
paraliane skeletons, isolated from E. paralias. In this assay, one of the isolated compounds 
showed high activity, comparable to that found for pepluanone.82 Moreover, they 
investigated the anti-inflammatory activity of six compounds with pepluane and paraliane 
skeletons. The results showed that all compounds have NO2
- production inhibitory activity in 
LPS-stimulated J774 macrophages by iNOS. They demonstrated the crucial role of a carbonyl 
on the D-ring and the negative effects when the D-ring is either hydroxylated or aromatic, 
suggesting the possible involvement of the D-ring structure in the inhibition of NF-κB 
activation.105 
Nunomura et al. investigated the effects of 3-O-(2,3-dimethylbutanoyl)-13-O-
decanoylingenol (DBDI), isolated previously from the roots of E. kansui,108 on the activation 
of intracellular signalling pathways and the release of inflammatory chemical mediators in 
bone marrow-derived mouse mast cells (BMMCs) upon FcεRI stimulation. It was revealed 
that DBDI significantly inhibits the [Ca2+]i increase, the β-hexosaminidase release and the 
synthesis of PGD2, PGE2 and LTC4 in BMMCs stimulated with IgE and multivalent antigen 
complex. Moreover, they demonstrated that DBDI inhibits the activation of intracellular 
signalling molecules, including Syk, PLC-γ2 and ERKI/2.109 
In 2010, Chang et al. reported that IL-6-induced Stat3 activation was inhibited by 
kansuinine A and B in HepG2 cells. Moreover, they established that ERK1/2 activation by 
these compounds play an important role in the downregulation of IL-6-induced Stat3 
activation.110 
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5.5. Antimicrobial activity 
 
Antiviral activity: The main problem of virus eradication in patients treated with highly active 
antiretroviral therapy is the persistence of latent HIV-infected cellular reservoirs.8 Prostratin 
and other non-tumorigenic PKC agonists have the ability to reactivate HIV-1 latency in vitro 
by activating NF-κB through a PKC-dependent pathway.56 Avila et al. investigated the effects 
of extracts and fractions from the latex of E. laurifolia and E. lactea on HIV-1 reactivation in 
Jurkat-LAT-GFP cells. Moreover, the bioactivity of the isolated diterpenes (69 and 70) was 
also investigated.56 3,12-Di-O-acetyl-8-O-tigloylingol, obtained from E. lactea, showed HIV-1 
latency reactivating activity in a concentration-dependent manner with an EC50 of 0.5 µg/mL 
and reaching maximal GFP induction at 5 µg/mL (84.3%). Other investigated compounds 
were significantly less active [33% (69) and 0% (70) at 25 µg/mL]. Due to the structural 
similarity between 3,12-di-O-acetyl-8-O-tigloylingol and phorbol esters such as PMA and 
prostratin, the role of PKC in 3,12-di-O-acetyl-8-O-tigloylingol-induced HIV-1 reactivation was 
studied. It was concluded that 3,12-di-O-acetyl-8-O-tigloylingol reactivates HIV-1 through a 
PKC-dependent pathway. Moreover, the conformational relation of cyclopentyl and the 
parent skeleton and the stereochemistry of the side-chain are responsible for this 
pharmacological effect.56 
Bedoya et al. investigated the antiviral activity of a series of previously isolated 
jatrophane diterpenes. It was confirmed that one of the compounds, SJ23B, exerted 
remarkable antiviral effect through the downregulation of HIV receptors and the induction 
of viral reactivation. In this investigation, the activity of SJ23B was 10-fold more potent than 
that of prostratin. Moreover, this jatrophane diterpene was able to activate PKC and cells 
where HIV is hidden as a latent provirus.111 
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Tian et al. investigated the antiviral activities of lathyrane diterpenoids (59, 64–68, 
71–74, 78, 80–85), isolated from E. micractina. It was established that 15-
cinnamoyloxylathyra-5,12-dien-3-ol-14-one (73) exhibited activity against HIV-1 replication 
(IC50 = 8.2 μM) in vitro. 
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Antibacterial activity: Screening of the in vitro antibacterial activities of guyonianin C (29) 
and D (31) by El-Bassouny on Gram-positive (Bacillus cereus and Staphylococcus aureus) and 
Gram-negative (Serratia sp. and Pseudomonas sp.) bacteria, demonstrated that guyonianin C 
(29) possesses activity against B. cereus.5 
 
5.6. Vascular relaxing activity 
 
Lathyrane diterpenoids (64–68, 71–74, 78, 80–85) isolated from E. micractina 
displayed substantial vascular-relaxing activities on phenylephrine-induced vasoconstriction 
model, with relaxation rates of 41–53%; the positive control verapamil exhibited a 44% 
relaxation at the same concentration.55 
Xu et al. investigated the inhibitory activities of lathyrane diterpenes isolated from E. 
prolifera on LPS-induced NO production in murine microglial BV-2 cells. Compounds 103 and 
15-O-acetyl-17-hydroxyjolkinol showed dose-dependent inhibition with IC50 values of 14.56 
and 82.56 μM, respectively. (12E,2S,3S,4R,5R,6S,9S,11S,15R)-3-benzoyloxy-5,15-diacetoxy-
6,17-epoxylathyra-12-en-14-one showed weak inhibitory effect (IC50 113.5 μM), and 
(12E,2S,3S,4R,5R,6S,9S,11S,15R)-3-propionyloxy-5,15-diacetoxy-6,17-epoxylathyra-12-en-14-
one was inactive. Neither of the tested compounds possessed remarkable cytotoxic effect on 
the BV-2 cells at their effective concentrations.57 
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5.7. Neuroprotective effect 
 
Xu et al. investigated the neuroprotective effect of 19 myrsinol type diterpenes (113, 
114, 118–120, 125, 126, 140, 141, 145, 14-deoxo-3-O-propionyl-5,15-di-O-acetyl-7-O-
benzoylmyrsinol 14β-acetate, euphorprolitherin C, 14-deoxo-3-O-propionyl-5,15-di-O-acetyl-
7-O-benzoylmyrsinol 4β-nicotinoate, proliferin A–C, euphorprolitherin B, SPr5 and 
premyrsinol-3-propanoate-5-benzoate-7,13,17-triacetate) isolated from E. prolifera. The 
activities were tested against MPP+ (1-methyl-4-phenylpyridinium ion)-induced neuronal cell 
death in SH-SY5Y cells using MTT assay at concentrations 3, 10 and 30 μM, and guanosine as 
a standard. All the compounds revealed to have neuroprotective effects. The active 
compounds neither modified the cell viability nor exhibited any cytotoxicity.62 Later, the 
same group investigated the neuroprotective effect of three myrsinol (115–117) diterpenes. 
Compounds 115 and 117 exhibited neuroprotective activities.65 
 
5.8. Proinflammatory activity 
 
Shu et al. investigated the proinflammatory constituents of E. kansui. The results 
showed that kansuinines A and B and 3-O-(2’E,4’Z-decadienoyl)-20-O-acetylingenol markedly 
facilitated proliferation of the splenic lymphocytes of exoteric mice and NO production by 
rat peritoneal macrophages at the used concentrations (from 0.78 to 12.50 μg/mL). The 
three compounds are therefore held to be the compounds responsible for the 
proinflammatory activity of the roots of E. kansui.112 It was also observed that kansuinines A 
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and B displayed anticancer and antiviral activities,113,114 so these diterpenes are belived as 
the main bioactive and toxic compounds of the plant. 
Ingenane-type diterpenes (196–205) isolated from E. cauducifolia showed ID50 = 2.5–
4.4 μg/mL, indicated moderate irritant activity of the compounds compared to TPA. 
Compound 197 was the most irritant in the series, other esters showed less irritant activity. 
None of the tested ingenanes showed tumor promoting effect up to a dose of 40 
nM/application after 48 weeks, compared to the standard TPA.80 
 
5.9. Pesticidal activity 
 
The MeOH extract of the roots of E. kansui exerted pesticidal activity against the 
brown plant hopper (Nilaparvatal ugens Stal) and the two-spotted spider mite (Tetranychus 
urticae Koch). Bioassay-directed separations led to the isolation of 3-O-(2,3-
dimethylbutanoyl)-13-O-dodecanoylingenol and 3-O-(2’E,4’Z-decadienoyl)-ingenol. The two 
diterpenes showed greater activity against the brown plant hopper as compared with anise 
oil and eugenol. The calculated LD50 doses were 0.139 μg/insect for 3-O-(2,3-
dimethylbutanoyl)-13-O-dodecanoylingenol and 0.111 μg/insect for 3-O-(2’E,4’Z-
decadienoyl)-ingenol.115 
Geng et al. investigated the feeding deterrent activities of diterpenes isolated from E. 
fischeriana. Significant feeding deterrent activity was found in case of jolkinolide B and 
hydroxyjolkinolide B against Sitophilus zeamais (EC50 = 342.1 and 543.9 ppm, respectively) 
and Tribolium castaneum adults (EC50 = 361.4 and 551.5 ppm, respectively).
25 
 
5.10. Molluscicidal activity 
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Baloch et al. investigated the molluscicidal activities of extracts (CCl4, Et2O, CHCl3, 
Me2CO, EtOAc, EtOH and MeOH) of the roots of E. cornigera, on the freshwater snail 
Biomphalaria glabrata, an intermediate host of Schistosoma mamsoni.78 Bayluscide was 
used as positive control. The Me2CO extract displayed significant activity (IC50 = 15.5 µg/mL). 
Further purification of this extract resulted in the isolation of ten ingenol-type diterpene 
polyesters. Eight of the isolated compounds [206–209, 212, 213, 3-O-[N-(2-
aminobenzoyl)]anthraniloyl-20-O-acetylingenol and 20-O-[N-(2-aminobenzoyl)]anthraniloyl-
3-O-acetylingenol] exhibited relatively high activity (1.3-2.2 times more toxic than 
bayluscide) against the intermediate snails. It was observed that these components were 
responsible for this activity.78 
Later, Baloch et al. investigated the molluscicidal effects of 8 phorbol derivatives 
(151–158) isolated from E. cauducifolia against B. glabrata snails. Two compounds, with an 
acetyl (151) or an N-(2-aminobenzoyl)anthraniloyloxy (152) moiety at C-13, had higher 
activities than that of bayluscide, while other compounds showed the same potency than 
that of the control niclosamide. The compounds probably provoke osmosnailic instability 
and surface vesiculation, causing the death of the snails.73 
Using a bioassay-guided fractionation of methanol extract of E. aellenii, two lathyrane 
diterpenoids (101 and 102) were isolated by Ayatollahi et al. The cytotoxicity of fractions 
was tested in vitro on brine shrimp (Artemia saline).54 
 
6. Clinical studies 
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There is only one compound, ingenol mebutate (ingenol 3-angelate, formerly 
PEP005), isolated from Euphorbia peplus,116 which has been used in clinical practice. 
Numerous clinical studies have been performed with this compound. Siller et al. evaluated 
the safety of two applications of ingenol mebutate gel in a randomized, double-blind, 
vehicle-controlled, phase IIa study. Preselected lesions were treated with 0.0025%, 0.01% or 
0.05% ingenol mebutate gel or vehicle gel, on days 1 and 2 or 1 and 8. No substantial 
differences in efficacy or tolerability were detected between the two applications, and the 
treatment was well tolerated.117 Ingenol mebutate gel was later investigated as topical 
application for superficial basal cell carcinoma in 60 patients, and it was observed that the 
treatment of 0.05% ingenol mebutate gel was effective and safe.118 
In a randomized, double-blind, double-dummy, vehicle-controlled, sequential cohort 
dose-finding study, Anderson et al. evaluated the efficacy, tolerability and safety of ingenol 
mebutate gel as topical therapy for actinic keratosis. In the phase IIb study, 0.025% ingenol 
mebutate gel was used once daily for 3 days, or 0.05% was applied once daily on 2 or 3 
consecutive days, to a continuous area of skin containing actinic keratosis lesions. It was 
concluded that the application of ingenol mebutate gel either for 2 or 3 days produced a 
statistically significant, greater lesion clearance by all measures of efficacy and at each of the 
dosing regimens studied as compared with the vehicle gel.119 Phase III data are also 
available, in connection with the use of ingenol mebutate on the scalp, face, arm, back of the 
hand, and chest.120 
Resiniferatoxin (RTX), like capsaicin, is an ultrapotent vanilloid receptor agonist, 
isolated from the latex of Euphorbia resinifera. RTX activates the transient receptor potential 
vanilloid 1 (TRPV1), a Ca2+ permeant non-selective cation channel expressed in a 
subpopulation of primary afferent sensory neurons (involved in nociception).121 RTX is 
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therefore promising lead molecule for the therapy of long-lasting analgesia. It has also been 
investigated in clinical trials for bladder hyperreflexia, diabetic neuropathy and cancer 
pain.122–124 
 
7. Synthesis of Euphorbia diterpenes 
 
In 2007, a diastereoselective synthesis of polyoxygenated atisane-type diterpenes 
was elaborated by Abad et al. (S)-(+)-Carvone served as starting material.125 In the course of 
the preparation an intramolecular Diels–Alder reaction, intramolecular diazoketone 
cyclopropanation of an unsaturated ketone and a endocyclic regioselective cleavage of a 
cyclopropyl carbinyl radical were applied. 18-Hydroxy-16-atisene-3,14-dione, isolated 
previously from E. fidjiana, has also been synthesized.125 
In 1989, the total synthesis of (±)-jolkinolides A, B and E from 10-(methoxycarbonyl)-
β-ionone was performed by Katsumura et al. The synthetic route contained approximately 
20 reaction steps.126 Later, Shi et al. modified this total synthesis, using easily available and 
low-cost stevioside as starting material, and prepared in 13 steps jolkinolide A and 19-
hydroxyjolkinolide E in an overall yield of 7.8%. Some related derivatives have also been 
synthetized.127 Suenaga et al. achieved the first total synthesis of the enantiomer of 
jolkinolide D from abietic acid.128 
Naturally occurring jatrophane polyesters, which contain many stereocenters and 
ester groups, such as with acetyl, nicotinoyl or benzoyl groups, have been isolated in several 
Euphorbia species.129 Previously different biological activities have been published for 
jatrophane diterpenes, e.g. multidrug resistance-modulating activity, and inhibition of P-gp, 
cytotoxicity against various human cancer cell lines, and immunomodulatory, antiviral, and 
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antiplasmodial activities. These findings, together with the unique structure of the 
jatrophane skeleton, have prompted synthetic experiments by many groups.129 The first 
total synthesis of a jatrophane type diterpene, named normethyljatrophone was carried out 
by Smith et al., in 1981.130 Later, Stille et al. elaborated another synthetic route. The key step 
in their experiment was the palladium-catalyzed intramolecular carbonylative coupling of 
vinyl stannane with vinyl triflate.131 Mulzer et al. and Hiersemann et al. also reported 
synthetic studies targeting jatrophanes. The key reactions were a Claisen–Eschenmoser 
rearrangement, and thereafter hydroxy-lactonization, intramolecular trans-lactonization, 
Davis hydroxylation and regioselective enoltriflate formation.132–135 In 2007, Shimokawa et 
al. subsequently described a short and striking synthesis of the cyclopentane fragment of 
kansuinine A using SmI2-mediated cyclization of the δ-iodoester as a key step,129 and 
Helmboldt et al. reported the enantioselective synthesis of a jatrophane-type diterpene, (+)-
17-norcharaciol.136 
The enantioselective total synthesis of the jatrophane (−)-15-O-acetyl-3-O-
propionylcharaciol was carried out by Schnabel et al.137 Starting from a cyclopentane, a β-
alkyl Suzuki−Miyaura cross-coupling and carbonyl addition were carried out to construct a 
fully functionalized triene, and a ring-closing metathesis was then applied to produce the 12-
membered ring (Figures 2a, 2b and 2c).137,138 
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Figure 2a. Synthetic route toward the production of a jatrophane diterpene structural 
fragment137 a) i: LiAlH4, THF, rt (90%); ii: Me2C(OMe)2, PPTS, CH2Cl2, rt (85%); iii: O3, CH2Cl2, 
MeOH, –78 °C, PPh3 (90%); b) i: CBr4, PPh3, CH2Cl2, –78 °C; ii: MeLi, THF, –78 °C; MeI, –78 °C 
to rt (78%); c) Cp2Zr(H)Cl, THF, 40 °C, 1.5 h then I2, CH2Cl2, (80%) 
 
 
 
 
 
Figure 2b. Synthetic route toward the production of a jatrophane diterpene structural 
fragment137 a) (PhSe)2, NaBH4, MeOH, 0 °C, 30 min, to rt (91%); b) LiNi-Pr2, i-PrCN, Et2O, 0 °C 
to rt (93%); c) i-Bu2AlH, toluene, –78 °C, 1h (81%); d) BrMgCH=CH2, THF, –78 °C, 45 min 
(76%); e) NAH, PMBCl, n-Bu4NI, THF, DMSO (90%) 
 
 
 
 
 
 
 
 
 
Figure 2c. Total synthesis of a jatrophane diterpene137 a) 9-BBN, THF, 40 °C, 24 h, + II (100 
mol %), (dppf)PdCl2 (7 mol %), Ph3As (20 mol %), Cs2CO3 (270 mol %), THF, DMF, H2O 
a 
b 
c 
d 
e 
II 
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c 
d 
e 
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III 
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(14/2/1), 80 °C, 8 h (86%); b) i: H2O2, NaHCO3, H2O, THF, rt (68%); ii: La(NO3)3·6H2O, MeCN, 
50 °C (54%); iii: IBX, CH2Cl2, DMSO (1/1), rt (81%); c) i: H2C=C(Me)Br, t-BuLi, THF, –78 °C, 15 
min (91%); ii: DDQ, CH2Cl2, aq. pH 7 buffer, rt, 2.5 h; iii: IBX, CH2Cl2, DMSO (1/1), rt, 6 h 
(75%); d) i: III (10 mol %), toluene (c = 1.3×10-3 mol/L), 110 °C, 2 h; ii: HF·Py, THF, 0 °C, 3 h; e) 
i: PPh3, DIAC, p-Br-C6H4COOH, THF, 0 °C (87%); ii: MeOH, K2CO3, rt, 5 h (91%) 
Later, Schnabel and co-workers reported the total synthetic routes toward natural 
and non-natural jatropha-5,12-dienes, applying a β-alkyl Suzuki–Miyaura cross-coupling for 
the construction of the C-5/C-6 olefin bond, and a ring-closing metathesis for the formation 
of the double bond between C-12 and C-13.139 In 2012, Mohan et al. applied a thermal 
intramolecular carbonyl-ene reaction to accomplish the highly substituted cyclopentane part 
of the molecule.140 
Duarte et al. derivatized latilagascene B, previously isolated from E. lagasce, with 
acylating reagents (benzoyl chloride, propionic anhydride and butyric anhydride) to yield 
three new lathyrane esters: latilagascene G, H and I.98 
Appendino et al. demonstrated that macrocyclic diterpenoids (e.g. the lathyrane type 
Euphorbia factors L1 and L3) can be conversed to densely functionalized diterpenoids with 
unnatural framework. The utilized starting compounds are easily available from the seeds of 
the caper spurge (E. lathyris) and have a pronounced potential to generate rigid polycyclic 
skeletons.141 
 Ingenol has also been of great interest not only because of its unusual structure 
containing an “inside-outside” bridged BC ring, but also because of a broad spectrum of 
pharmacological activities. The synthesis of the highly strained ingenane framework required 
special approaches, and strategically distinct methods.142–144 The first total synthesis of 
ingenol was performed by Winkler with the use of an intramolecular de Mayo reaction.145 
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Other successful synthetic approaches (Winkler, Wood and Tanino/Kuwajima) and promising 
partial syntheses have since been reported and reviewed (Figure 3).146–153 In 1997, 
Nakamura et al. carried out an efficient method for the synthesis of ingenane by application 
of a tandem cyclization–rearrangement involving the complete C and D ring structure of 
ingenol, although the methoxy group at position C-4 was not sufficient to serve as an anchor 
for incorporation of the hydroxy groups and the double bonds of the A and B rings.154 Later, 
they described the total synthesis of ingenol on the basis of another strategy from a 
commercially available compound. A rearrangement of an epoxy alcohol afforded the key 
intermediate, which is substituted with two oxygen functions (at C-1 and C-6).151 In 2002, 
Rigby et al. elaborated a facile entry into the ingenane core by developing a Lewis acid-
catalyzed intramolecular [6+4] cycloaddition.155 The main challenges concerning the 
synthesis stems from the strained ‘in-out’ [4.4.1]-bicycloundecane ring and the highly 
oxygenated and densely functionalized southern part of the molecule. 
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Figure 3. Wood’s total synthesis of ingenol152 a) i: (HOCH2)2, pTsOH, C6H6, Δ, 96%, dr= 
43:23:18:16; ii: LiAlH4, Et2O; iii: HCl, acetone, H2O, 95% (2 steps); b) i: Ac2O, pyridine, DMAP, 
96%; ii: DBU, C6H6, Δ, 80%; c) cyclopentadiene, BF3·OEt2, PhCH3, –78 °C, 59%; d) Grubbs-I, 
ethylene, CH2Cl2, 98%; e) i: OsO4, NMO, THF–H2O 4:1; ii: NaIO4, MeOH–THF 4:1; iii. (HOCH2)2, 
pTsOH, C6H6, Δ, 73% (3 steps); f) ClCH2C(=CH2)CH2OPMB, KH, THF, Δ, 98%; g) RCM, PhCH3, Δ, 
76%; h) i: HCl, THF–H2O, Δ; ii: NaBH4, EtOH–THF, 0 °C, 77% (2 steps); iii: I2, PPh3, imidazole, 
THF, 0 °C; iv: KOtBu, THF–DMSO, 94% (2 steps); i) i: SeO2, 
tBuOOH, CH2Cl2–H2O–HOAc, 0 °C, 
rt, 68% brsm; ii: Dess-Martin periodinane (DMP), CH2Cl2, –40 → 10 °C, 74%; iii: RhCl3, EtOH, 
115 °C, 74%; j) KOtBu, O2, P(OMe)3, THF, 
tBuOH 4:1, –40 °C, 94%; k) VO(acac)2, 
tBuOOH, C6H6, 
10 °C to rt, 73%; l) i: TMSOTf, Net3, CH2Cl2, –10 °C to –5 °C, 72%; ii: NaBH4, MeOH; iii: 2.2-
DMP, PPTS, CH2Cl2, Δ, 86% (2 steps); m) i: DDQ, CH2Cl2, 90%; ii: MsCl, Net3, CH2Cl2, –78 °C, 
96%; iii: PhSH, Li2CO3, DMF, 55 °C, 76%; iv: (NH4)6Mo7O24, H2O2, EtOH, 97%; n) DBU, C6H6, Δ, 
47%; o) i: Na–Hg, Na2HPO4, MeOH, –20 → –10 °C, 76%; ii: HCl, THF–H2O, 92%; iii: SeO2/SiO2, 
THF, 80 °C, 85% brsm. 
 The structurally related phorbol and its analogs were synthetized by Wender et al. in 
1990. The interesting feature of this process was an unprecedented silicon transfer-induced 
oxidopyrilium cycloaddition and transition metal-mediated synthesis of ring A.156 
 
8. Conclusions 
 
In the past few years, more than 200 novel diterpenes with rosane, ent-abietane, ent-
atisane, ent-kaurane, casbane, jatrophane, lathyrane, myrsinane, premyrsinane, 
cyclomyrsinane, daphnane, tigliane, ingenane, paraliane or pepluane skeletons have been 
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isolated from different Euphorbia species. Many of the investigated species contain 
constituents with two or more different cores. Some Euphorbia species (E. prolifera, E. esula, 
E. kansui, E. cornigera and E. cauducifolia) are especially rich in diterpenes. Diterpenes are 
considered to be important taxonomic markers of the Euphorbiaceae family, because of 
their limited occurrence and structural diversity. 
Dimeric and glycosylated diterpenes in Euphorbia species are very rare. The first 
dimeric diterpenoids were langduin C and D, isolated from E. fischeriana in 2003 by ZHOU et 
al.157 In 2012, Zhang et al. obtained two other dimers (bisyinshanic acids A and B) from E. 
yinshanica.29 Only one glycosylated Euphorbia diterpene is known, discovered in E. 
helioscopia in 2010.53 
In some cases, the diterpenes of given Euphorbia species of different origins have 
been found to be different, e.g. in the case of E. esula. Samples from different locations 
(China, Hungary, and North America) contained different diterpenes (jatrophanes, 
ingenanes).158–166 In the diterpene series obtained from the Hungarian collection, the 
aromatic acyl residues were missing and the alcohol core of the compounds was different 
from that isolated from North American and Chinese samples. As concerns the diterpene 
composition, E. esula displays many similarities with E. salicifolia. These species contain the 
same main diterpene components (esulatin A, salicinolide and euphosalicine), and other 
jatrophanes differing only in the esterification pattern (number and position of ester 
groups).167,168 In case of E. peplus, different investigations jatrophane, ingenane and 
pepluane diterpenes have been reported. The diterpenes of the samples originating from 
Chile, Germany and Hungary were found to be similar, while from an Italian sample, 
different compounds were isolated.45,83,169,170 These facts indicated that in case of E. peplus 
chemovarietas must presumably be exist. 
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All Euphorbia species produce a white milky sap (latex), which is exuded when they 
are injured. The common name of the Euphorbiaceae family is the spurge family. This is 
derived from the Medieval French “epurger,” which means “to purge”.171 The sap of many 
herbaceous Euphorbia species has traditionally been used as a purgative, or laxative. 
Moreover, several Euphorbia species have been applied in traditional medicine against 
various tumors.172 However, their application in modern therapy is impossible because of 
the irritant and tumor-promoting activities of certain diterpenes occurring in the latex. The 
toxic constituents of Euphorbia species are the ‘phorboids’, which comprise ingenane, 
daphnane and tigliane diterpenes.173 
Biologically active compounds of traditional medicinal plants are frequently utilized in 
the pharmaceutical industry either as active agents of medicines or as lead compounds in 
drug development. Almost 70% of modern drugs had a natural product origin.174 The 
importance of this type of natural products may be demonstrated primarily by the approval 
of ingenol mebutate (Picato®) by the FDA and EMA for the treatment of actinic keratosis a 
pre-cancerous skin condition. This compound isolated from E. peplus for the first time by 
Hohmann et al.170 It has been a considerable time since a natural product without structural 
modification has been introduced into clinical practice. Some other ingenol and phorbol 
derivatives (e.g. prostratin), have become of considerable interest in HIV therapy. In 
combination with other antiretroviral drugs they can activate viral reservoirs and overwhelm 
the pool of latent HIV infection. Resiniferatoxin which acts by destroying nerves that 
transmit pain information is at present undergoing evaluation in phase II and III clinical 
trials.175 
Recent pharmacological experiments encompassed the assessment of 
antiproliferative, cytotoxic, MDR inhibitory, anti-inflammatory, immunomodulatory, 
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antimicrobial, vascular relaxing, neuroprotective, pesticidal and molluscicidal activities. 
These results open up new opportunities primarily in the design and development of drugs 
against tumors and to overcome the multidrug resistance of human cancers. 
Investigation of the diterpenoids of Euphorbias is very promising. The hit probability 
of the search for new natural compounds is noteworthy: the Euphorbia species produce a 
great number of previously undiscovered compounds (almost 70% of the isolated 
compounds are new). Approximately 100 Euphorbia species have so far been investigated 
for diterpene content, i.e. only less than 5% of the species belonging in this genus. 
Moreover, the analytical (primarily HPLC) studies of constituents as biomarkers and 
correlations of biological and/or toxic effects of Euphorbias may be helpful in discovering the 
mechanisms of their bioactivity, and for guiding safer application of these species in the 
clinic.13 
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